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ABSTRACT
CAUSAL INFERENCE IN HEALTHCARE: APPROACHES TO CAUSAL
MODELING AND REASONING THROUGH GRAPHICAL CAUSAL MODELS
Riddhiman Adib, M.S.
Marquette University, 2022

In the era of big data, researchers have access to large healthcare datasets
collected over a long period. These datasets hold valuable information, frequently
investigated using traditional Machine Learning algorithms or Neural Networks.
These algorithms perform great in finding patterns out of datasets (as a predictive
machine); however, the models lack extensive interpretability to be used in the
healthcare sector (as an explainable machine). Without exploring underlying causal
relationships, the algorithms fail to explain their reasoning. Causal Inference, a
relatively newer branch of Artificial Intelligence, deals with interpretability and
portrays causal relationships in data through graphical models. It explores the issue
of causality and works towards an explainability of underlying causal models deeply
buried in data.
For this dissertation work, the research goal is to use Causal Inference to
build an applied framework that lets researchers leverage observational datasets in
understanding causal relationships between features. To achieve that, we focus on
specific objectives such as (a) the addition of background knowledge to causal
structure learning algorithms, (b) the proposal of new causal inference
methodologies, (c) generation of theories connecting causality to standard statistical
analyses (e.g., Odds Ratio, Survival Analysis), and (d) application of proposed
approaches in real-world healthcare problems. This dissertation encapsulates the
tasks mentioned above, through various new methodologies and experiments under
the rubric of Structural Theory of Causation. We discuss the common research
theme in causal inference, historical development, the structural theory of causation,
and underlying assumptions. Finally, we explore the impact of these proposed
methodologies in real-world treatment controversy of Delirium patients, by
examining the efficacy of antipsychotic drugs prescribed in treating Delirium in the
ICU, from a curated observational healthcare dataset.

i
ACKNOWLEDGMENTS
Riddhiman Adib, M.S.

I am thrilled and ecstatic today, expressing my acknowledgment for the most
remarkable achievement of my life. My Ph.D. in Computer Science is a hard-earned
one, coming from a background in Electrical Engineering and studying in a foreign
land. And now that I am here, I would love to mention and pay respect to all the
people who have supported me in my journey to this day.
Firstly, I would like to express my sincerest gratitude to my Ph.D. advisor,
Dr. Sheikh Iqbal Ahamed, for his support throughout my doctoral studies.
Graduate school is a demanding time for the students; without constant
encouragement, guidance, and comfort of a caring supervisor, this is an impossible
feat to complete.
I sincerely believe that every star and moon aligned perfectly until this
moment in my life to let me have this incredible moment and earn this great honor.
Every person, who contributed somehow to my life, deserves recognition in my
gratitude. I would like to start with my wonderful childhood at Banasree, Dhaka,
my childhood and school friends, and my buddies at Ideal School and College. My
teachers at Ideal School and a wonderful year (grade 6) at MSC Cadet Coaching
built the base of my future; they shaped me into who I am now.
From grade 7 to 12 (middle school & high school), I went through a fantastic
journey at Jhenidah Cadet College. Everything I am right now and will be in the
future is because of my cadet college. This military school taught me perseverance,
discipline, and the value of hard work above everything. I got a lifetime of amazing
friends and peers from my cadet college days. After that, I got a fantastic
opportunity to learn from and with the best in Bangladesh during my undergrad in
EEE at BUET. BUET took us through a rigorous curriculum; however, it also let
me have my bit of fun and independence on the campus. And I got another set of
awesome friends here as well.
I am fortunate to have renowned mentors in my life. I have learned a lot at
my job at Harriken.com and BanglaTrac Technologies from my mentors and
colleagues. In my grad school, I had a prominent opportunity to learn from and
work with Dr. Adibuzzaman. He has guided me relentlessly and helped me find my
passion in research. This dissertation is an outcome of our continuous brainstorming
and ideations over the last four years. With that, I would also like to thank my

ii
professors at Marquette and my external collaborators: Dr. Osmani, Dr. Paul, Dr.
Madiraju, Dr. Stacee, and Dr. Norah.
Milwaukee has been my home for the last 5 years, for my whole grad life.
This is a fantastic city with a stunning lake beside us; this is a blessing for someone
who loves living beside water bodies. I have met great friends and peers here. I
want to thank my dearest friends who have been with us through thick and thin, my
department buddies at Cudahy Hall, Marquette, and my fellow lab members (past
& present).
I am lucky enough to have a pair of wonderful and caring parents, Jessmin
Akter & Md. Abdur Rahman. They have supported me with whatever whimsical
wishes I wanted to pursue in my life; they have also taught me to be caring,
respectful, cautious, and inquisitive. My younger brother, Taskin Sabit Rudra, has
always been one of my greatest advocates and well-wisher. He has always been by
my side and one of the exemplary guys one could have as a brother. I also want to
thank my cousin, Bellah, who has literally taught me everything I know. He has
been a mentor from my early childhood for long nine years (2000-2009), and he is
the best teacher I have ever witnessed in my life. His two most significant gifts were:
(1) understanding and relying on ‘logic’ in life, and, (2) teaching me how to learn
topics by myself. I would also like to thank my constant well-wishers: my cousins
(puchkis), aunts (khalas-mamas-chachus), grandparents (nanu & dadu-dadi), and
my extended family.
Last but not least, I want to acknowledge the person without any of this
would not happen (or even if it had happened, it would not have any value), my
constant support, my rock, and the best buddy a guy could ask for; my wife,
Jannatul Ferdause Tumpa. I am blessed to have her on this crazy journey, and we
both completed our Ph.D. together at Marquette. Since my early undergrad years, I
have had her on my side; and together, we have ridden through extraordinary times,
sometimes rough but mostly fun. I want to thank Tumpa for being my partner in
this incredible ride and supporting me to this day. As I am writing this now and
wrapping up my Ph.D. works (and acknowledgment), in front of me is our little
bundle of joy, our firstborn, Audriyana Adib. She makes me feel that all of this:
relocation to a foreign land, staying apart from our family, the constant stress,
studying for the last 30 years, this is all worth it. Finally, before wrapping it up, I
want to mention all others in my life; I admire you all for contributing to my life
and supporting me to this point.

iii
TABLE OF CONTENTS

ACKNOWLEDGMENTS
LIST OF TABLES
LIST OF FIGURES
CHAPTER 1 Causal Inference and it’s Impact in Healthcare Research

i
vii
viii
1

1.1

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1

1.2

Big Data, Machine Learning, Causal Inference . . . . . . . . . . . . .

3

1.3

Background and Related Works . . . . . . . . . . . . . . . . . . . . .

5

1.3.1

Structural Theory of Causation . . . . . . . . . . . . . . . . .

5

1.3.2

Causal Structure Learning Algorithms . . . . . . . . . . . . .

6

1.3.3

Transportability and Causal Queries of Interest . . . . . . . .

7

1.3.4

Applied Causal Inference . . . . . . . . . . . . . . . . . . . . .

9

Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

10

1.4.1

Computational Significance . . . . . . . . . . . . . . . . . . .

11

1.4.2

Clinical Importance . . . . . . . . . . . . . . . . . . . . . . . .

12

1.5

Research Theme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

13

1.6

Research Questions . . . . . . . . . . . . . . . . . . . . . . . . . . . .

13

1.7

Organization of this Thesis . . . . . . . . . . . . . . . . . . . . . . . .

15

CHAPTER 2 CKH: Causal Knowledge Hierarchy for Estimating
Structural Causal Models from Data and Priors

17

1.4

2.1

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

17

2.2

Related Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

19

2.2.1

Structural Causal Models . . . . . . . . . . . . . . . . . . . .

20

2.2.2

Structure Learning Algorithms . . . . . . . . . . . . . . . . . .

22

iv
2.2.3

Inter-rater Agreement . . . . . . . . . . . . . . . . . . . . . .

24

2.2.4

Hierarchy of Evidence . . . . . . . . . . . . . . . . . . . . . .

26

2.2.5

State of the Art . . . . . . . . . . . . . . . . . . . . . . . . . .

27

Expert Augmented Causal Model with Knowledge Hierarchy . . . . .

29

2.3.1

Causal Knowledge Hierarchy . . . . . . . . . . . . . . . . . . .

29

2.3.2

Algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

35

2.4

Experimental Results . . . . . . . . . . . . . . . . . . . . . . . . . . .

41

2.5

Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

48

2.3

CHAPTER 3 A Causally Formulated Hazard Ratio Estimation through
Backdoor Adjustment on Structural Causal Model
53
3.1

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

53

3.1.1

Clinical Relevance

. . . . . . . . . . . . . . . . . . . . . . . .

57

3.1.2

Technical Significance . . . . . . . . . . . . . . . . . . . . . . .

57

3.1.3

Generalizable Insights . . . . . . . . . . . . . . . . . . . . . .

58

3.2

Related Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

59

3.3

Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

63

3.3.1

Hazard Ratio . . . . . . . . . . . . . . . . . . . . . . . . . . .

63

3.3.2

Structural Causal Models . . . . . . . . . . . . . . . . . . . .

65

3.3.3

Problem Definition . . . . . . . . . . . . . . . . . . . . . . . .

67

Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

67

3.4.1

Assumptions . . . . . . . . . . . . . . . . . . . . . . . . . . . .

68

3.4.2

Approach . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

70

Experiments and Applications . . . . . . . . . . . . . . . . . . . . . .

77

3.5.1

Experimental Data . . . . . . . . . . . . . . . . . . . . . . . .

77

3.5.2

Ewing’s Sarcoma Data . . . . . . . . . . . . . . . . . . . . . .

80

Discussion and Conclusion . . . . . . . . . . . . . . . . . . . . . . . .

82

3.4

3.5

3.6

v
CHAPTER 4 Pragmatic Clinical Trials in the Rubric of Structural
Causal Models

86

4.1

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

86

4.2

Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

87

4.2.1

Experimental Studies . . . . . . . . . . . . . . . . . . . . . . .

88

4.2.2

Pragmatic Clinical Trials . . . . . . . . . . . . . . . . . . . . .

89

4.2.3

Structural Causal Models . . . . . . . . . . . . . . . . . . . .

92

4.2.4

SCM for Scientific Studies . . . . . . . . . . . . . . . . . . . .

93

4.2.5

Problem Definition . . . . . . . . . . . . . . . . . . . . . . . .

94

4.2.6

Related Works . . . . . . . . . . . . . . . . . . . . . . . . . .

94

Structural Causal Model for Pragmatic Clinical Trials . . . . . . . . .

95

4.3.1

Defining PCT for SCM . . . . . . . . . . . . . . . . . . . . . .

96

4.3.2

Features of PCT . . . . . . . . . . . . . . . . . . . . . . . . .

97

4.3.3

Outcome Analysis for PCT

99

4.3

4.4

4.5

. . . . . . . . . . . . . . . . . . .

Example of PCT with SCM . . . . . . . . . . . . . . . . . . . . . . . 102
4.4.1

SCM for PCT . . . . . . . . . . . . . . . . . . . . . . . . . . . 104

4.4.2

Outcome Analysis . . . . . . . . . . . . . . . . . . . . . . . . . 104

Discussion and Conclusion . . . . . . . . . . . . . . . . . . . . . . . . 105

CHAPTER 5 Causal Discovery on the Effect of Antipsychotic Drugs
on Delirium Patients in the ICU using Large EHR Dataset
110
5.1

Background and Problem Statement . . . . . . . . . . . . . . . . . . 110

5.2

Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116

5.3

Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
5.3.1

Covariate Selection . . . . . . . . . . . . . . . . . . . . . . . . 117

5.3.2

Data Curation Process . . . . . . . . . . . . . . . . . . . . . . 119

5.3.3

Data Overview & Exploratory Insights . . . . . . . . . . . . . 119

5.3.4

Predictive Analysis on MIMIC-Delirium dataset . . . . . . . . 121

vi
5.3.5
5.4

Causal Analysis on MIMIC-Delirium dataset . . . . . . . . . . 122

Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127

CHAPTER 6 Conclusion and Future Work

130

6.1

Broader Impact and Summary Contribution of this dissertation . . . 130

6.2

Future Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132

BIBLIOGRAPHY

135

vii
LIST OF TABLES

2.1

Summary of different SLAs and their outputs . . . . . . . . . . . . .

24

2.2

Alteration in causal edges in the simulation

. . . . . . . . . . . . . .

47

2.3

Iterations of simulations with false information injected in each tier .

47

3.1

Hazard Ratio for simulated dataset, calculated using existing model
and our proposed approach . . . . . . . . . . . . . . . . . . . . . . . .

79

Hazard Ratio for Ewing dataset, calculated using existing model and
our proposed approach . . . . . . . . . . . . . . . . . . . . . . . . . .

82

3.2
4.1

Population distribution for different values of treatment prescribed X,
treatment received X 0 and outcome Y . . . . . . . . . . . . . . . . . 105

4.2

Outcome metrics for the PCT . . . . . . . . . . . . . . . . . . . . . . 105

5.1

Features in MIMIC-Delirium . . . . . . . . . . . . . . . . . . . . . . . 118

5.2

Outcomes estimation in Average Treatment Effects (ATE) . . . . . . 126

viii
LIST OF FIGURES

1.1

An example of a causal DAG

1.2

Two example Causal structure generated in two different studies. (Left)
Causal structure generated in the study of modelling air pollution, climate and health data. (Right) Causal structure generated in the study
of ct honeycombing with increased mortality for interstitial lung diseases

8

1.3

An example of a selection diagram

. . . . . . . . . . . . . . . . . . .

9

2.1

Simplest graphical model representing observational study with three
variables, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

21

2.2

Evidence-Based Medicine (EBM) Resources . . . . . . . . . . . . . .

27

2.3

General overview of causal structure generation pipeline using CKH .

30

2.4

Tiers of Causal Knowledge Source . . . . . . . . . . . . . . . . . . . .

31

2.5

Ground-truth Causal Model versus Structural Causal Models with edge
confidences at individual tiers of CKH . . . . . . . . . . . . . . . . .

42

2.6

Structural Causal Models as outputs of Tier 2 in CKH . . . . . . . .

46

3.1

An example survival curve, collected from Girard et al. ([34]) . . . . .

55

3.2

Schematic overview of the proposed approach . . . . . . . . . . . . .

68

3.3

Simple observational study (treatment X, outcome in survival-time T
and single confounder Z) . . . . . . . . . . . . . . . . . . . . . . . . .

69

Converted Causal DAGs with survival time converted to binary outcome of survival at different timepoints . . . . . . . . . . . . . . . . .

73

Unadjusted survival curve for simulated data (left) and, survival curve
generated after applying proposed approach (right) . . . . . . . . . .

79

Unadjusted survival curve for Ewing dataset (left) and, survival curve
generated after applying proposed approach (right) . . . . . . . . . .

81

Two example graphs where the backdoor adjustment will produce different results compared to an approach based on the ignorability assumption . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

83

3.4
3.5
3.6
3.7

. . . . . . . . . . . . . . . . . . . . . .

6

ix
4.1

Visualization of PRECIS (PRagmatic Explanatory Continuum Indicator Summary) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

91

4.2

SCM representation of scientific studies . . . . . . . . . . . . . . . . .

94

4.3

Graphical representation of the proposed structural causal model for
pragmatic clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . .

96

Graphical representation of the structural causal model of a RCTP CT ,
(left) with population Πs & treatment X (= X 0 ), and (right) with
population Πs as a selection bias through node S on population Z . .

97

4.4

4.5

Hypothetical PCT in patients with cardiovascular disease. Intervention, A = medical management + surgery, vs. control, B = medical
management only. Collected from McCoy et al. [76] . . . . . . . . . . 102

4.6

Graphical overview of SCM representation of the example PCT . . . 104

5.1

RCT for Antipsychotics-based treatment for Delirium . . . . . . . . . 112

5.2

Target observational study from large EHR data . . . . . . . . . . . . 115

5.3

Data mining protocol (simplified) . . . . . . . . . . . . . . . . . . . . 120

5.4

Data distribution on age in years (left) and length-of-stay in days (right)120

5.5

Correlation heatmap of MIMIC-Delirium . . . . . . . . . . . . . . . . 122

5.6

Combined Causal Graph for Delirium in the ICU (blue: treatment, red:
primary and secondary outcomes) . . . . . . . . . . . . . . . . . . . . 124

1
CHAPTER 1
Causal Inference and it’s Impact in Healthcare Research

1.1

Introduction

Causal inference methodologies, specially the structural theory of causation [91], has
shown potential to extract causal relationships from observational datasets based on
certain assumptions, and is now thoroughly explored and developed by scientists.
Structural theory of causation depicts experiments through causal directed acyclic
graphs, mitigates biases, and proposes theorems that aid in drawing causal
inferences from observational as well as experimental studies. However, since it is a
relatively newer subgroup of data science and artificial intelligence, we theorize that
Structural theory of causation has yet a lot more unexplored potential.

Experimental studies with varying designs and research goals, such as
Randomized Controlled Trials (RCT), Pragmatic Clinical Trials (PCT), are
frequently conducted in health sciences [116]. The general intent is to draw an
inference on treatment intervention (i.e., drug efficacy) on a specific population
group (i.e., patients under critical care, people over age 65) as well as the more
general population (i.e., hospital-admitted patients, elder-care facilities) under usual
care. However, due to differences in the experiment settings (i.e., adherence to drug
prescription, presence of control group), transfer of knowledge from one study to
another is not trivial [66], and therefore, making a general inference of intervention
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efficacy becomes unclear. It also hinders the usage of large-scale healthcare data
and merging of causal information from these observational datasets (Obs) [87].
Thus, there is a need for structural methodologies, assumptions, inferences and
information, to draw unbiased causal inferences from observational data, or from
one experiment to another, or in general, combining all of them (RCT+PCT+Obs),
leveraging their unique design attributes.

The objective of this research proposal is to scheme a set of methodologies
that can define studies with diverse experimental settings (RCT, PCT, Obs), make
inferences based on assumptions, and extract (and transfer) causal effects of
treatment interventions. Our in-depth understanding of the experiments and
underlying assumptions, along with ongoing research work on survival analysis from
observational studies using the structural theory of causation makes this research
proposal uniquely strong and plausible. Availability of publicly available large
healthcare datasets (MIMIC-III), extraction of dataset on focused experimental
scenario (e.g., delirium) with related covariates, and access to a real-world
pragmatic clinical trial dataset on 351 number of Intensive Care Unit (ICU) patients
make this proposal more credible in validating the generated hypotheses.

The general specific aims of this research are:
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• to aid in new novel/make amends for improvement of existing causal structure
learning algorithms based on observational dataset and assumptions,
• to generate a methdology to incorporate background knowledge in building
the causal structure,
• to propose novel methodolgies to extract casusal effect using source dataset,
target dataset and Causal model, and,
• to validate the proposed hypotheses using experimental and observational
dataset from antipsychotic drug usage on delirium-induced patients in the
ICU.

1.2

Big Data, Machine Learning, Causal Inference

In the era of ’Big Data,’ the world is transmitting an enormous amount of
information, their collection, storage, analysis has become a standard task in every
part of our life. The proposition of new statistical tools and models have enabled
machine learning processes to be applied to them, improvement of computation
power (GPU and parallel computing) have made designing neural network possible.

Researchers now have access to an enormous amount of observational data,
most of which are still unexplored and contains a great potential to possess causal
effects of particular interventions (drugs/practices/actions), similar to a clinical trial
[8]. The causal exploration is an ever-growing research problem for statisticians,
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mathematicians, computer scientists, and epidemiologists, extracting causal
information from observational data, as we do with experimental data.

Causal inference is the science of drawing conclusions on causal relationships,
depending on the conditions of the occurrence of the effects. Finding and
establishing a causal relationship is not as trivial as finding correlations between
variables; however, the process relies on them, along with certain assumptions
(discussed in later sections). The prime difference between causal inference and
association-driven inference is that the former explores the response of the effects
when the cause is manipulated/intervened. Causal inference lets scientists start
from association, move up to performing interventions, and finally rise to analyze
counterfactuals [13, 92].

Although Causal Inference shares some actions with machine learning
protocols, there are individual differences between them as well. The similarities are
in some of the model search and feature selection processes, overlapping of models,
scoring of models, etc. The dissimilarities are more prominent; the major one is,
machine learning focuses on prediction through curve-fitting [121]. It mostly does
not care or consider the cause of an outcome. Causal inference, on the other hand,
tries to define the underlying causal mechanism between variables. Another
significant difference is, causal inference contains the knowledge of the intervention,
which traditional machine learning models lack. Finally, causal inference requires a
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precise standard procedure of validation of results, since there is a lack of process to
gather ground-truth causal mechanisms. This lacking is one of the severe
impediments in the development of the science of causal inference.
1.3
1.3.1

Background and Related Works
Structural Theory of Causation

In Causal Inference, researchers build their works in two distinct directions: 1) using
Rubin Causal Model (RCM) [56, 107], based on potential outcomes framework, and,
2) using the structural theory of causation [89, 91], based on probabilistic graphical
models. We rely on the structural theory of causation since the graphical
representation of causal models opens up more opportunities for better
visualization, understanding, and clearer definitions (i.e., backdoor criterion) [6].
A structural causal model [91] is a 4-tuple {U, V, f, P (u)} where U is a set of
background (exogenous) variables that are determined by factors outside of the
model, V is a set {V 1, V 2, ..., V n} of observable (endogenous) variables that are
determined by variables in the model, F is a set of functions {f 1, f 2, ..., f n} such
that each f is a mapping from the respective domains of U to V, and P(u) is a
probability distribution over the exogenous variables. This is commonly represented
through a directed acyclic graph (Causal DAG) (Figure 1.1).

6

Figure 1.1: An example of a causal DAG

1.3.2

Causal Structure Learning Algorithms

One of the critical research areas in Causal inference is Causal structure learning
algorithms. Causal structure learning algorithms (SLA) are specific graph search
algorithms that detect causal structure expressed as graphs with nodes and edges,
from the conditional dependencies of in-between dataset variables and additional
assumptions [121]. Based on their approach and associated assumptions, causal
structure learning algorithms have been broadly categorized into five (5) categories
[44], such as constraint-based methods (e.g., Peter-Clark (PC), fast causal inference
(FCI)), score-based methods (e.g., greedy equivalence search (GES), greedy
interventional equivalence search (GIES), hybrid methods (e.g., max-min hill
climbing (MMHC)), structural equation models with additional restrictions (e.g.,
linear non-Gaussian acyclic models (LINGAM)), and, exploiting invariance
properties (e.g., backShift). Building and improving causal SLA is a high potential
research area in causal inference and has been applied many times to generate an
underlying causal structure given a specific scenario and dataset.
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There are multiple issues associated with causal SLAs, which are open
research problems. Most of the times, the algorithms are not very computationally
efficient (high runtime complexity), and fails to detect a causal structure. Lack of a
ground-truth makes them very hard to compare and diagnose. Change in
assumptions, missing data, lack of appropriate covariate data also makes them very
vulnerable to a false-positive result. A more robust approach is through the
ensembling of their findings. Epidemiologists have been continuously involving
causal structure learning algorithms for identifying underlying causal structures.
Different studies have taken different paths, few studies [128, 2] have used specific
SLA algorithms to detect a causal DAG applicable for a targeted research question,
whereas others [110, 10] have assumed the causal structure from literature, and
validated them using datasets available. Albeit their success in estimating causal
effects, due to strong assumptions, missing data, and general variation in
experiments, there are potential areas to explore and apply causal SLA in
epidemiology.

1.3.3

Transportability and Causal Queries of Interest

There are many causal queries in experiments researchers aim to explore. One area
of importance is transportability, which is a crucial feature in the structural theory
of causation, and still being explored in recent research works [13]. Transportability
presents research methodologies in Causal Inference, where experiments from the
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Figure 1.2: Two example Causal structure generated in two different studies. (Left)
Causal structure generated in the study of modelling air pollution, climate and health
data. (Right) Causal structure generated in the study of ct honeycombing with
increased mortality for interstitial lung diseases

source domain can be leveraged to answer a query in the target domain. Although
we focus on epidemiology in our proposal (under the keyword generalizability), this
research has an impact in other fields of science as well, under the keywords,
external validity in psychology, meta-analysis in statistics, transfer learning in
machine learning, etc. We represent causal mechanisms under transportability
through Selection diagrams (Figure 1.3), which is also a directed acyclic graph and
represents an overlap to causal diagrams of different studies along with selection
criteria as a node. Since our research aims to translate causal queries from one
study to another, theories of transportability are the most helpful tool. There are
additional other directions of causal inquiry in epidemiology: modeling of target
trial from observational data and related assumptions, causal modeling of survival
analysis, etc. We plan to aid in these explorations through causal inference.
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Figure 1.3: An example of a selection diagram

1.3.4

Applied Causal Inference

Theories of causal inference rely on observational data. Without applying our
theories, we cannot effectively claim the efficacy and validity of our proposed
approaches. During research works of prior summer practicum for research in
Computational sciences program, we worked on extracting an observational dataset
for delirium-induced patients in the Intensive Care Unit (ICU) from large
observational data sets along with various covariates correlated with delirium. We
utilized the MIMIC III database [58], extensive electronic health records dataset
with 53,423 distinct hospital admissions. We defined a target trial, and based on the
target trial, we extracted information of the subject group diagnosed with delirium
(ICD9 code 293.0) from the MIMIC III database and conducted a retrospective
cohort analysis. We categorized them into three groups based on commonly
prescribed antipsychotic drugs (APD); patients prescribed Haloperidol, other APD,
and no APD. Primary outcomes are death in hospital and death timeline (death in
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30 days / 90 days / a year). Secondary outcomes contain length-of-stay in the ICU,
and time-in-mechanical ventilation.
1.4

Motivation

The motivation of this research is to generate standardized methodologies aiding in
the transfer of knowledge from or between experimental studies and observational
studies. We aim to build methods that can define studies with diverse experimental
settings (RCT, PCT, Observational) and extract causal effects of treatment
interventions, along with validation through the incorporation of observational and
experimental datasets, exploring the efficacy of antipsychotic drugs (APD) on
delirium-induced patients in the ICU.

The proposed research activities make notable contributions directly to the
field of Statistical Science, Machine Learning, and Epidemiology. However, the
underlying causal theories are not only limited to a specific branch of science, rather
discuss scientific inquiries overall [69]. Our proposed methodology will: 1) build a
bridge between experimental studies and observational studies, and thus open the
opportunity to use a large amount of observational data we have access to, 2)
showcase a procedure for researchers to use to draw causal inference from datasets
(experimental or observational) in consideration to their design features, and 3)
provide an insight on the mental causal model scientists consider while designing an
experiment.
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1.4.1

Computational Significance

The ability to translate scientific findings in one experimental setting and transfer
to a different one is a vital process of the scientific investigation. Inference
techniques are highly sought in Epidemiology, Sociology, Finance, Psychology, etc.
and theories of causal inference have shown great promises in quantifying the causal
effects in these fields.

The research area of emulating experiments (RCT/PCT) using an
observational dataset is highly expected but relatively newer, and still contains
many controversies. Researchers have shown the possibility of using observational
datasets to emulate RCTs for antiretroviral therapy (Lodi et al. 2019) and ARDS
(Bikak et al. 2018). We plan to build our approach on top of these existing research
works and find novel ways to address the shortcomings. Our proposed research plan
will be focused on: 1) to propose a standard statistical and computational
framework to build (emulate) experiments (RCT/PCT) from Observational dataset
with minimal bias, 2) to propose Causal Inference approach to existing statistical
methodologies, like transportability, Survival Analysis, 3) to showcase a new way to
explore large datasets and interpret their underlying causal structure.

Our proposed methodology aims to lower the gaps between experimental and
observational studies and to generate an unbiased causal effect estimation from
dissimilar datasets with varying experimental settings. The method and pipeline
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can provide the initial results for more extensive studies and a complete framework
for the application of causal inference methods in other diseases and interventions.

1.4.2

Clinical Importance

While RCTs are the gold standard to identify causal effects of interventions [41], it
is time-consuming and costly. On the other hand, the data collected during routine
care (i.e., electronic health records (EHR)) might also be valuable in generating
insight, identifying the disease pathway, and estimating interventions’ effect using
methods for causal inference.

The motivation behind applying the proposed methodology, specifically in
Delirium-induced patients in the ICU, comes from antipsychotic drugs’ use in its
treatment and the controversies around it. Delirium frequently occurs in the
Intensive Care Unit (ICU) (up to 80% cases [35]) and is associated with longer
hospital stay (10% increased mortality for each additional day [96]). Delirium is
commonly treated with antipsychotic drugs (APD) such as haloperidol and
ziprasidone. However, multiple randomized controlled trials (RCTs) have shown
either conflicting or inconclusive results about the efficacy of APD in the treatment
of delirium [82, 42]. This calls for an efficacy analysis from a separate standpoint,
resulting from observational datasets collected over a longer time-period and wider
population demography.
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1.5

Research Theme

The general research theme of this proposal is to develop application methodologies
of Causal inference in extracting causal information from an observational dataset.
We hypothesize that, compared to traditional statistical methodologies and machine
learning models, causal inference is more suitable for manipulating observational
and experimental data. Our proposed methodologies will contribute to building
foundations for that.

The specific aims are planned to distribute the research plans into four
distinct and significant parts, specific aim 1 addresses theoretical prospects of using
the structural theory of causation in defining scientific studies, specific aim 2
explores methods to apply background knowledge in generating causal structures,
specific aim 3 focuses on specific theories, assumptions, methodologies of extracting
causal information (through transportability, causal survival analysis, etc.) under
the framework, and specific aim 4 explores application and validation of our
proposed methodology in a real-world research problem scenario.
1.6

Research Questions

Driven by the research motivations and based on the research theme, the specific
aims for our research proposal are:
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• Research Aim 1: We aim to propose a generalized process of learning
simplified Causal Model from observational datasets.

– Causal structure learning (Proposal of new or results/performance of old
ones)
– Assumptions for causal structure learning
– Ensembling results from structure learning algorithms
– Reduced-order causal graph

• Research Aim 2: We plan to collaborate with information from other
sources (domain knowledge, literature, experts’ opinion) to the causal model
generated from observational data.

– Incorporation of background knowledge in the causal graph
– Idea of Knowledge gathering and collaborating from multiple sources:
from experts’ experience, from literature, from observational datasets
available
– Building of a standardized dictionary dataset of causal connections
between variables under scenarios
– Possibility of contribution to reduced-order causal graph generation

• Research Aim 3: We aim exploration of ways to generate optimum
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responses to causal queries for a specific population and extract that
information using source dataset, target dataset, and a causal model.

– Specific methodologies/ algorithms to extract causal information from
causal graph and data
– Issues involving transportability
– Definition and assumptions for experiments (e.g., Pragmatic trial, RCT)
– Causal survival analysis

• Research Aim 4: We plan to apply the idea of extracting causal information
from observational data, as described above, in real-world clinical problems.

– Specific clinical/epidemiological application through Causal inference
– Efficacy of Antipsychotic drug on delirium-induced patients in the ICU

1.7

Organization of this Thesis

Elaborating upon the research theme explored and aims defined, the remainder of
this thesis describes various methodologies and experiments aiding to the plan. In
chapter 2, we propose a Causal Knowledge Hierarchy to build robust causal
structure from data and other sources of information. In chapter 3, we will present
a use of do-calculus on structural causal models, to estimate causally formulated
hazard ratio for survival analysis. In chapter 4, we will discuss an ideation of
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structural causal models for specific trials conducted in healthcare research,
specifically pragmatic clinical trials. In chapter 5, we will apply the previously
discussed causal inference methodologies to a real-world problem, estimating
efficacy of Antipsychotics in treatment of Delirium in the ICU, through use of large
healthcare dataset. Finally, we will conclude with research summary, contributions
and future works in chapter 6.
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CHAPTER 2
CKH: Causal Knowledge Hierarchy for Estimating Structural Causal
Models from Data and Priors

2.1

Introduction

Causal knowledge discovery or identifying cause-and-effect relationships between
variables is a fundamental objective in various domains such as epidemiology and
medicine [102], sociology [33], and economics [37]. Without understanding causal
relationships, scientists rely on correlations, which do not allow for estimation of
intervention effect (i.e., doing) of a variable on a model outcome. While randomized
controlled trials remain the gold standard for exploring causation [65], they are
often infeasible because of cost, time, and/or ethical reasons [36]. Thus, causal
discovery from observational data that is complementary to experimental studies is
of significant interest [46, 73, 84].

Recent developments in the theory of causal inference under the Pearl causal
hierarchy (PCH) [95, 94, 13], also known as structural theory of causation (within
the potential outcome framework) provides the methodologies to estimate causal
effects from observational data. Within this, a causal model is expressed through
structural causal models (SCMs) [90]. SCMs represent variables of interest
(exogenous and endogenous), causal relationships between the variables, and
underlying probability distributions. SCMs use a graphical representation of the
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causal model, formalize the identification of causal effects from observational and
experimental data, estimate the interventional distribution (P (y|do(x))) through
do-calculus [93], and assess hypothetical scenarios from available data and model
with necessary assumptions explicitly encoded into the model.

PCH is grounded in the three layers of causation: (L1 ) seeing, (L2 ) doing,
and (L3 ) imagining. Recent work on the causal hierarchy theorem (CHT) proved
that discovery in a higher layer of causation using only information from a lower
layer is not feasible [11]. In other words, estimating the effect of experimentation
(i.e., “doing (L2 )”) is not feasible based only on observational data (i.e., “seeing
(L1 )” ) [11]. Hence it is critical to augment observational data (L1 ) with other
sources of information such as expert knowledge to derive the effect of intervention.
Expert knowledge can come in different forms such as expert opinions, established
causal relationships and, peer-reviewed literature [26]. Within each of these forms,
confidence in knowledge can vary. However, no methodological framework exists for
incorporating domain expertise with data-driven causal discovery from observational
data in a systematic way [122].

We develop a methodological framework to augment data-driven causal
discovery tools with human in the loop (HTL) models. The additional causal
knowledge sources include different tiers of knowledge, but is not limited to:
background knowledge, expert opinion, and literature. For this purpose, we have
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broadly categorized possible causal knowledge sources into three tiers and proposed
a causal knowledge hierarchy (CKH) between the tiers. Using this causal knowledge
hierarchy, we develop an associated standardized methodology to curate necessary
causal information and merge them to derive the structural causal model (SCM).
We also provide both theoretical and simulated results of the framework along with
algorithmic pseudo code detailing the implementation.

We make the following specific contributions in this work:

1. We propose a causal knowledge hierarchy (CKH) on the foundation of levels of
evidence in medicine based on the confidence in the causal information.
2. We present a standard methodological pipeline, based on CKH, to capture
causal knowledge from different sources and combine them to derive the SCM.
3. We show the effectiveness of our proposed method in a simulated experiment,
detailing the implementation, along with evaluation.

2.2

Related Work

Before presenting our proposed methodology we briefly discuss the relevant scientific
concepts needed to explain the individual steps as well as the rationale behind
them. The objective of our method is to generate an expert augmented Structural
Causal Model (SCM) for a specific hypothesis, where part of the causal
information used to generate the graphical representation comes from the
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application of Structure learning algorithms on datasets. The building blocks of
our proposed methodology includes structural causal models (SCM), Inter-rater
agreement functions for generating aggregated information and a Causal
Knowledge Hierarchy inspired from Hierarchy of Evidence in evidence-based
health research. These concepts are introduced in this section with details.

2.2.1

Structural Causal Models

Developed on the foundations of probabilistic graphical models, SCMs are graphical
representations of the causal relationships between variables, and are used to draw
causal inferences. An SCM is often expressed by a causal graph G. Each node V in
G represents an observed or unobserved variable, and each directed edge E
represents the causal relationships between them.
An SCM M is a 4-tuple hU, V, f, P (u)i [89] where,

• U is a set of background (exogenous) variables that are determined by factors
outside of the model,
• V is a set of observable (endogenous) variables that are determined by
variables in the model,
• F is a set of functions such that each fi ⊆ F is a mapping from the respective
domains of Ui ∪ P Ai to Vi , where Ui ⊆ U and
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Figure 2.1: Simplest graphical model representing observational study with three
variables,

• P Ai ⊆ V \ Vi and the entire set F forms a mapping from U to V , and P (u) is
a probability distribution over the exogenous variables.

A simple structural causal model, with treatment X, outcome Y and
confounder Z, is expressed using causal directed acyclic graph (nodes are the
variables, edges portray causal relationships between variables) in Figure 2.1.

To find the causal effect of variable X on variable Y , do-calculus is
introduced [95]. Do-calculus comes with its own set of strong mathematical tools,
such as, rules of do-calculus, backdoor criterion, that is used to map the
observational reality to the corresponding experimental reality with the
identifiability equation by adjusting for different kinds of biases (e.g., confounding
bias), if it exists.

Figure 2.1 represents a simple graphical model for an SCM. Although an
SCM is used to represent the underlying causal model, in reality, the ground truth
causal model in social sciences or medical sciences is never fully known [30]. The
causal graph usually represents a set of assumptions explicitly in the problem
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domain of interest. Given a data set, an SCM can be any of the causal model for a
Markov equivalence class [119], meaning multiple causal models can be true within
a Markov equivalence class for a given data set. Consequently, the validation of a
causal model is one of the fundamental challenges in causal inference research. The
state of the art generates the most-fitting SCM from datasets using structure
learning algorithms (described in next subsection) using the properties of conditional
probability distributions.

2.2.2

Structure Learning Algorithms

Other than domain expertise, observational or experimental data can be used to
generate a causal graph. Data are the result or snapshot of the underlying causal
mechanisms between variables. To recover the causal relationships from data, a rich
set of algorithms have been developed over the past thirty years [118, 127, 115].
Causal structured learning is where we try to learn the causal graph or aspects of
the causal mechanism. The problem is fundamentally a model selection problem,
and these algorithms are called structured learning algorithms (SLA) [44, 25], where
a graph is learned or estimated that best describes the dependence structure in a
given data set. The learning process includes relying on necessary assumptions (i.e.,
causal sufficiency, causal faithfulness, linearity), finding conditional dependencies
between variables (i.e., Bayes’ theorem) and differentiating between different causal
structures (i.e., chains, forks, colliders).
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Specifically, learning an SCM (or, Bayesian Networks) with a directed acyclic
graph (DAG) G and parameters θ from a dataset D with n observations is
completed in two steps [111]: (1) finding the DAG G which encodes the dependence
structure of data D, called structured learning, and (2) estimating the parameters θ,
given the obtained G from structured learning, called parameter learning:

P (G, θ|D) = P (G|D) · P (θ|G, D)

Consequently, SLAs are a key component in estimating causal effects within a
dataset.

Several algorithms have been proposed in the literature for SLAs [44],
however they differ in their approaches, assumptions, and graphical objects
generated. This makes their outcomes varying (even based on the same data source)
and difficult to compare.

The main classes of existing SLAs [44] are:

1. Constraint-based methods: Peter-Clark (PC), rankPC , fast causal
inference (FCI), and rankFCI
2. Score-based methods: greedy equivalence search (GES), rankGES, greedy
interventional equivalence search (GIES), and rankGIES
3. Hybrid methods: Max-min hill climbing (MMHC)
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PC
Causal sufficiency
Yes
Causal faithfulness
Yes
Acyclicity
Yes
Non-gaussian errors
No
Known do-intervention No
Output
CPDAG

FCI
No
Yes
Yes
No
No
PAG

GES
GIES
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
Yes
CPDAG PDAG

MMHC
Yes
Yes
Yes
No
No
DAG

LINGAM
Yes
No
Yes
Yes
Yes
DAG

Table 2.1: Summary of different SLAs and their outputs

4. Structural equation models with additional restrictions: linear
non-Gaussian acyclic models(LINGAM)

An overview of their generated graphical models and assumptions required
are summarised in Table 2.1.

Since different SLAs can generate different SCMs from the same datasets,
there is a need for a principled approach for combining information, which is also
correlated with the agreement between them. For this purpose, we leverage
inter-rater agreement functions (described in next section) to generate an aggregated
graphical model that best represents the data along with other sources of causal
information (e.g., output SCMs of SLAs, expert opinion or peer-reviewed literature).

2.2.3

Inter-rater Agreement

Inter-rater agreement [77] is the degree of agreement among raters, which generates
a score on homogeneity, or consensus, in the ratings given by judges or raters. In
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causal inference we frequently arrive at multiple ratings on causal relationships (by
experts’ opinion, or from outputs of SLAs), and this is a mechanism to mitigate the
discrepancy. To the best of our knowledge, this mechanism has not been previously
used in the context of causal graph generation.

Inter-rater agreement function relies on three operational definitions of
agreement [108]:

1. Reliable raters agree with the “official” rating of a performance.
2. Reliable raters agree with each other about the exact ratings to be awarded.
3. Reliable raters agree about which performance is better and which is worse.

In addition, reliable raters are assumed to behave as independent witnesses
to the model where they express their independence by disagreeing slightly. In our
proposed methodology, we assume the expert opinion, literature, or SLAs are
independent raters of causal relationships who capture and express their judgements
based on their individual knowledge sources.

Different types of inter-rater agreement functions and scores have been
proposed, each with their unique features and strengths. We present a brief
overview [77] of a few of them here.

1. Percent agreement
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2. Cohen’s kappa coefficient
3. Fleiss kappa (adaptation of Cohen’s kappa for 3 or more raters)
4. Joint probability of agreement
5. Pearson r coefficient
6. Krippendorff’s alpha (useful when there are multiple raters and multiple
possible ratings)

Along with inter-rater agreement function applied on rated causal
relationships between variables by raters or algorithms, we propose to incorporate
the well established Hierarchy of Evidence in evidence-based health research in
our methodology.

2.2.4

Hierarchy of Evidence

A hierarchy of evidence is needed when there are multiple results or inferences from
similar scientific studies (sometimes even contradictory) and one has to choose one
or combine them. Hierarchy of evidence (or, levels of evidence) is a scoring that
quantifies the rank or strength of the results or outcomes from scientific and
experimental studies. The hierarchy relies on the study design, validity and
applicability to patient care, and quality of data [1]. When choosing between
multiple findings from experimental studies, hierarchy of evidence is critically
important. For example, in healthcare professionals are required to decide on
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Figure 2.2: Evidence-Based Medicine (EBM) Resources

clinical actions based on the best evidence available. One of the most significant
reasons behind using a hierarchy of evidence is to upgrade quality of care, by
identifying and promoting practice that is effective and by eliminating those who
are ineffective or harmful [5].

Different hierarchy of evidence have been proposed in the literature, based on
design of studies and the endpoints measured. A commonly accepted level of
effectiveness rating scheme [1] is presented in Figure 2.2.

2.2.5

State of the Art

The need for causal inference from sources other than data has been explored in the
literature [122]. From a theoretical perspective, research has been conducted on
integrating causal information from varying sources. Lee et al. [70] proposed
GID-PO that identifies the causal effect from partially-observed distributions. In
another result [71], an algorithmic approach that combines data collected under
multiple, disparate regimes (observational and interventional) to identify specific
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causal effects was presented. However, the focus of these experiments was not on
prior knowledge or varying knowledge sources. Borboudakis et al. [16] used
path-constraints to incorporate prior causal knowledge, without explicitly discussing
the impact of causal knowledge sources. For tiered knowledge, Andrews et al. [7]
proposed tiered background knowledge where each tier consists of sets of variables
with causal relationships, preceding another set of variables (aka, tier), and
demonstrated that FCI (Fast Causal Inference) is a sound and complete causal
structure elarning algorithm with and incorporation of this knowledge. From an
empirical viewpoint, [86] developed a causal model from medical literature and
electronic medical record (EMR) data, by generating two independent graphs, one
based on the literature and one from the EMR data, and merged them. The method
did not consider other sources of knowledge and did not compare knowledge sources
as well as their confidence of information. In a related result, a
prior-knowledge-based causal discovery algorithm [129] has been proposed to
discover the underlying causal mechanism between bone mineral density and its
factors from the clinical data, where prior knowledge was handpicked manually and
added to the algorithm as a whitelist between edges. Finally, from a software
application perspective, a graphically similar software application to help
researchers navigate published findings has been proposed by the software
“ResearchMaps” [67]. However, this is primarily a visualization tool to illustrate
interconnected features with a graph. In summary, although previous research has
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attempted to resolve causal information from varying sources, a unified and
principled approach to build a generic SCM is still needed.
2.3

Expert Augmented Causal Model with Knowledge Hierarchy

We propose the concept of tiers of causal knowledge and the generalized algorithm
for causal model learning through knowledge hierarchy. Specifically, we propose
Causal Knowledge Hierarchy (CKH) that uses three tiers of knowledge analogous to
the “hierarchy of evidence” [1] and the associated weight for each tier. We discuss
the assumptions within the CKH required for our proposed methodology. Finally,
we establish step-by-step actions for the method. Our approach starts with the
inputs: problem statement (PS), defined keywords (K), (empty) structural causal
model (SCM), pre-defined tier weights (W), and Inter-rater agreement function
(IRR) (discussed in supplementary document). For each tier, a general series of
steps is described. Finally, the SCM goes through an edge orientation phase to
produce the fully specified SCM with individual edge weights (hU, V, F, P (u), CE i).
An overview of our method is presented in Figure 2.3.

2.3.1

Causal Knowledge Hierarchy

Levels of evidence [1], is a well established knowledge hierarchy based on the study
design, data collection, and sample size. Based on this concept we propose a
“Causal Knowledge Hierarchy (CKH)” to incorporate causal information from
different sources. CKH is a multi-level descriptor between types of knowledge and
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Figure 2.3: General overview of causal structure generation pipeline using CKH

their contribution to the overall causal structure in a problem domain. We initially
define three common sources of causal information and propose a hierarchy between
them. We define necessary assumptions to make our proposed framework effective
and generalizable. We categorize sources of causal knowledge for scientific studies
into three distinct classes and define a hierarchy (CKH) based on the statistical
confidence in the causal information they hold.

Definition 1 The three tiers of the CKH are: (1) Tier 1: Causal knowledge
from expert opinion / expertise (CKE ), (2) Tier 2: Causal knowledge
from data (CKD ), and (3) Tier 3: Causal knowledge from peer-reviewed
literature (CKL ). The target structural causal model is a function of convex
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Figure 2.4: Tiers of Causal Knowledge Source

combination of causal knowledges from the three tiers of sources,

SCM ← f (CKE , CKD , CKL )

Tier 1: Causal Knowledge from Expert Opinion

Tier 1 of CKH incorporates causal knowledge based on the expertise and opinions
(CKE ) from researchers, scientists, and, subject matter experts (SME). This
includes, but is not limited to, inputs from physicians, discussion with application
users and intervention participants and, by researchers working in a specific problem
domain; and excludes any knowledge directly from peer-reviewed literature. Causal
knowledge is generally captured through surveys or structured communications’
methods-driven group discussions (e.g., Delphi method [72]). This collaborative
knowledge requires further validitation through scientific studies, and is prone to
high levels of bias due to variation in the expert’s training and experience. We
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classify this causal knowledge as Tier 1 (CKE ), and assign a lower weight (WE )
since it contributes diverse information with lesser confidence.

Tier 2: Causal Knowledge from Data

Tier 2 encodes causal knowledge generated from data sources (CKD ). Data can be
from various study designs such as an experimental study (e.g., data from
randomized controlled trials), an observational study (e.g., text mining data from
social media), or in between (e.g., data from pragmatic clinical trial). Depending on
the data generation mechanism, different structural causal models are used to
explain the causal relationships between the variables. However, there may be bias
from selection, confounding, or other experimental design features. We associate the
causal knowledge gathered from data (CKD ) at Tier 2, with a relatively higher
weight (WD ) than that of Tier 1 (CKE ). The rationale for this is: (a) data can be
collected from different study designs, locations, and corroborated over time, (b)
data can be analyzed further with newer methodologies and models, and (c) data
can convey the effect of causal relationships between covariates for scientific studies.
Because of the higher weights, it contributes more to that conjoined causal model,
and can even alter directions of certain causal relationships defined from Tier 1.
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Tier 3: Causal Knowledge from Literature

Tier 3 is causal information from peer-reviewed literature (CKL ) and has the
highest weight in the CKH. It excludes any knowledge from opinions of experts,
without references. Examples of Tier 3 include causal knowledge from peer-reviewed
and published literature, systematic reviews, meta-analyses, evidence syntheses,
article synopses, and causal effect of interventions published as studies. Within Tier
3, there may be different levels of evidence. The data extraction process
additionally falls under the domain of text-mining and natural language processing
(NLP). Causal knowledge from literature (CKL ) may have its own biases such as
selection bias for inclusion exclusion criteria or transportability bias for differences
in population.

Tier Weights for Causal Knowledge Hierarchy

Axiom 1 Each tier of causal knowledge hierarchy (CKH) has individual weights
(WE , WD , WL ), signifying the confidence of the causal information. A higher tier
holds a higher weight and provides more robust causal information compared to that
from lower tiers. By definition,

CKE ∝ WE , CKD ∝ WD , CKL ∝ WL

Based on the causal information hierarchy proposed, we define three weights
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W = {WE , WD , WL } for each tier of the causal knowledge hierarchy (refer to Axiom
1 ). The weights are defined such that:

1.

P

i

Wi = 1: By definition of convex combination, the sum of all three tier

P
weights ( W = WE + WD + WL ) is 1.0. A full agreement for a specific edge
connection and direction from all three tiers of the CKH results in maximum
edge confidence of 1.0.
2. WE < WD < WL : The weights are defined in an increasing order. At any
time, causal information from one tier can only contribute a maximum of their
tier weight. Thus, this increasing score ensures a hierarchy between each tier.

The weights are not fixed values and depend on the specific research question
as well as availability of causal knowledge for the specific research question.
Practically, the weights are hyper-parameters to the proposition and need to be
agreed upon by researchers while generating the structural causal model.

Assumptions

For our proposed methodological framework, there are two associated assumptions.

Assumption 1 Knowledge within the same tier of CKH does not override one
another.
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For conflict resolutions with contradictory causal information within the
same tier (such as, A → B from dataset 1 and A ← B from dataset 2, both from
CKD ),we find the strength of the causal relationship based on all the information
within the same tier. Selection of knowledge sources within a tier is subjective and
depends on the experimenter. Consequently, we do not propose any hierarchy
within a tier, rather, we compute the conjoined strength of the causal connections.
A similar direction in causal connections and edges increase the confidence, whereas
contradictory causal connections and edges reduce the confidence of the edge.

Assumption 2 Within CKH, knowledge from upper tier (or, in special case, tier
with more weight) can reverse/ override knowledge from lower tier.

Unlike the earlier assumption, when we have contradictory causal
information from different tiers (such as, A → B from Tier 1 (CKE ) and A ← B
from Tier 2 (CKD )), the direction of causal relationship from an upper tier can
override that from a lower tier.

2.3.2

Algorithm

Our algorithm works with the following inputs: problem statement (PS), defined
keywords (K), (empty) structural causal model (SCM), pre-defined tier weights
(W), and inter-rater agreement function (IRR). For each of the three tiers of CKH,
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we encode specific and relevant causal knowledge within the tier, and systematically
update the knowledge base to derive the causal structure.

We start with an empty SCM, with no values assigned to U, V, F and P(u)
(introduced and discussed in the supplementary document). For each individual tier
of causal knowledge hierarchy, we follow the steps described below:

1. Encode tier-specific information: For each tier, we encode all the
information in the causal graph specific to that tier. Specifically, we encode:

(a) experts’ opinion and background knowledge as individual edges, and
their confidence score (between 0 and 1.0) in those edges (with
directions), in Tier 1 (CKE ),
(b) edges generated by the causal structure learning algorithms run on the
data sets, in Tier 2 (CKD ), and,
(c) causal relationships extracted from literature as directional edges in Tier
3 (CKL ).

2. Develop a scoring matrix from encoded information: From the
information encoded for each tier, we build a causal information-based scoring
matrix P for the specific tier, with a dimension of m × n. Here m is the
number of rows equal to the count of unique pairs of nodes (variables). For q
number of total variables (U ∪ V ) in an individual tier, we have
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m=

q
2



=

q(q−1)
.
2

n is the number of columns in the scoring matrix P . For a

specific row in P with the nodes (or variables) A and B, we have four columns
signifying the type of causal connection between them: i) A → B, ii) A ← B,
iii) no causal connection between A and B and, iv) no causal information
available between A and B. The complete matrix represents the causal
knowledge in the specific tier.
3. Compute individual edge confidence based on agreement from
scoring matrix: Next we calculate individual edge confidence from each row
in the scoring matrix P , through plurality voting. For each pair of nodes A, B
in P , we iterate through rows i of P and use the equation of edge confidence
of causal connections between variables A and B:

qi = [Pi (n)] for n = 0, 1, 2

eA,B =

max(qi )
P
qi

(2.1)

(2.2)

Here, eA,B signifies the confidence of the causal connection or on the
directional edge between variables A & B, qi represents the first three values
of row i of scoring matrix P with variables A and B.
4. Estimate agreement score from the scoring matrix: Using the
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inter-rater agreement function (IRR), we calculate the agreement score (α)
(i.e., Fleiss’ kappa, varies from 0 to 1) from the generated scoring matrix P
(explained further under background in supplementary document).
5. Compute individual weighted edge confidence: Next, we calculate the
weighted edge strength for all edges within a tier, using the equation:

weighted eA,B = eA,B × α × Wi

(2.3)

Here, weighted eA,B signifies the weighted edge confidence of the causal
connection between variables A & B, α is the agreement score calculated
previously, and Wi represents the weight of the specific tier (WE / WD / WL ).
Within a specific tier, only eA,B is different for individual edges, whereas α
and Wi remains the same. In the best case, where edge weight for a specific
edge and agreement score are both 1.0, the weighted edge strength can be the
maximum (the weight of the Tier).
6. Extract tier-specific insights: From the generated weighted edge
confidences weighted eA,B , we extract tier-specific causal insights and carry
them forward to the next tier. Specifically, in Tier 1 (CKE ), we set a
predefined confidence threshold to select edge whitelist. Any edge with edge
confidence over the threshold is put in the whitelist and used in the structure
learning algorithms in Tier 2 (CKD ). Similarly, in Tier 2 (CKD ), we extract
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an incomplete causal structure skeleton hU, V, F i and probability distribution
hP (u)i, to carry over to the next tier. Finally, in Tier 3 (CKL ), we extract the
complete SCM hU, V, F, P (u)i, with encoded information from all tiers of the
CKH.
7. Move extracted insights to next step: Next we get the output of the
specific tier, the extracted insights and use them in the next tier as inputs.

Edge Orientation Step: In this step, we check for any potential cycles between
variables, and re-orient them prioritizing the weighted edge strengths, and generate
a complete directed acyclic graph. For this task, we implement the edge orientation
process from PC algorithm [111]. For each triplet of nodes, A − B − C, we
recursively set edge directions using the two rules: (a) if A is adjacent to B and
there is a strictly directed path from A to B, we then replace A − B with A → B
(to avoid introducing cycle), and (b) if A and C are not adjacent and we have
A → B & B − C, we replace B − C with B → C (to avoid introducing new
v-structures). The complete directed acyclic graph, along with the computed
hU, V, F, P (u)i is the resultant SCM for the problem domain. The algorithmic
pseudocode is presented in Algorithm 12.
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Algorithm 1 Structural Causal Model Estimation using Causal Knowledge Hierarchy
(CKH)
1:
2:
3:
4:
5:
6:
7:
8:
9:

procedure Estimation-by-CKH(P S, K, SCM , W , IRR)
Initialize empty confidence for all edges: CON F ← φ
Update modified SCM for output: SCMm ← SCM + CON F
Select group of experts: Exp ← [exp1 , exp2 , exp3 , ...]
. (a) Tier 1: CKE
while expert expi in Exp do
0
CRCK
[i] ← extract causal relationships(expi , P S, K, U ∪ V = φ)
E
0
U, V ← get vars(CRCK
)
E
while expert expi in Exp do
00
[i] ← extract causal relationships(expi , P S, K, U ∪ V )
CRCK
E

00
0
)
∪ CRCK
U, V ← get vars(CRCK
E
E
00
0
)
11:
P ← create grading tuple(CRCKE ∪ CRCK
E
12:
F, CON F ← compute weighted conf idence(WE , P, IRR, SCMm )
13:
SCMm ← update scm(SCMm , [U, V, F, CON F ])
14:
Using U ∪ V and K, gather relelvant datasets: D = [d1 , d2 , d3 , ...] . (b) Tier
2: CKD
15:
Select different causal structure learning algorithms: SLA = [sla1 , sla2 , sla3 ]
16:
while output model in SLA × D do
0
[i] ← extract causal relationships(model)
17:
CRCK
D

10:

18:
19:
20:
21:
22:
23:

0
)
U, V ← get vars(CRCK
D
P (u) ← get probability distribution(D)
0
)
P ← create grading tuple(CRCK
D
F, CON F ← compute weighted conf idence(WD , P, IRR, SCMm )
SCMm ← update scm(SCMm , [U, V, F, P (u), CON F ])
Using P S and K, gather relevant literature: L = [l1 , l2 , l3 , ...] . (c) Tier 3:

CKL
24:
U, V ← get vars(L)
25:
while literature l in L do
0
26:
CRCK
[i] ← extract causal relationships(L)
L
27:
28:
29:
30:
31:

0
P ← create grading tuple(CRCK
)
L
F, CON F ← compute weighted conf idence(WL , P, IRR, SCMm )
SCMm ← update scm(SCMm , [U, V, F, CON F ])
SCMm ← orient edges(SCMm )
. (d) Edge orientation
return SCMm = hU, V, F, P (u), CON F i
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Algorithm 2 Computation of Weighted Confidence for Individual Tier
1:
2:
3:
4:
5:
6:
7:
8:
9:

2.4

procedure compute weighted confidence(W, P, IRR, SCM )
Measure agreement score: α ← IRR(P )
CON F ← φ
while edge in SCM do
Equation 1 and 2 to find edge confidence: Cedge
Equation 3 to find weighted edge confidence: weighted Cedge
CON F.append(weighted Cedge )
F ← extract edge connections(P )
return F, CON F
Experimental Results

For our experiments, we rely on a simulation with a standard causal model. We use
pre-defined default values for hyper-parameters, and validate our results with the
initial ground truth causal model and provide sensitivity analysis of the SCM.

Ground Truth Causal Model We start the simulation with a causal model
with a ground truth SCM (Figure 2.5), (a). For this, we refer to the “clgaussian”
dataset from ‘bnlearn’ library [64]. The dataset has 5000 data-points and is
generated from a causal model with one normal (Gaussian) variable, four discrete
variables and three conditional Gaussian variables. For validation, we assume this
initially defined causal model to be the Ground Truth Directed Acyclic Graph
(GTDAG).

Optimization Function Keywords are defined with a complete set of variables
{A, B, C, D, E, F, G, H}. We define the optimization problem to identify the causal
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Figure 2.5: Ground-truth Causal Model versus Structural Causal Models with edge
confidences at individual tiers of CKH

effect and relations between variables D and G, along with all associated variables
{A, B, C, E, F } with the best-fitting GTDAG for the SCM. We also hypothesize
that the domain is well-explored (with sufficient experts, data and literature) and set
the values of weights as WT 1 = 0.2, WT 2 = 0.3, WT 3 = 0.5, as well as confidence
threshold for Tier 1 threshold = 0.8.

Tier 1: Causal Knowledge from Experts’ Opinion For Tier 1, we consider
only one expert Exp = {exp1 }, and use their knowledge, expressed through causal
graphs (although in reality, we might have multiple experts). We go through this
step in two phases, the first causal graphs are encoded from each of the experts by
describing the problem statements (P S) and keywords (K). We integrate all the
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variables and create a super-set of nodes, U ∪ V . The second causal graph is derived
after providing U ∪ V , along with both P S and K to the experts. This generates 2x
causal graphs from experts’ opinions based on the problem statement. From these
graphs, we generate simplified causal connections:

• A → D, confidence: 0.5
• D → G, confidence: 1.0
• B → E, confidence: 1.0

Based on the pre-defined confidence threshold for Tier 1, we derive a
combined causal graph from them. In the combined causal graph in Tier 1, we have
M =< U, V, F, P (u) = φ, CON F = φ >, where U and V comes from the super-set
of variables suggested by the experts, and F is defined from the causal relationships
suggested by the experts. We calculate the agreement score (using Kappam’ fleiss),
and measure total confidence values using the agreement score and WT 1 = 0.2. Since
we use one expert in this experiment, the agreement score for this tier is 1.0, and we
use this value in Equation 3 to compute the weighted edge confidence. We build our
scoring matrix P based on the weighted edge confidence higher than the confidence
threshold. The resulting causal graph after Tier 1 is presented in Figure 2.5, (b).
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Tier 2: Causal Knowledge from Data For Tier 2, we generate three separate
datasets, D = {d1 , d2 , d3 } based on the GTDAG. To simulate a varying number of
datasets in real-world, we generate and use three different datasets for which the
underlying causal relations are invariant. d1 , is generated from variables {A, D, G},
d2 , is generated from only variables {B, D, E, G, H}, and d3 , is generated from all
the variables. We use two specific structure learning algorithms, SLA = {sla1 , sla2 },
with sla1 being PC algorithm and sla2 being MMHC algorithm. Additionally,
we use edge whitelists from Tier 1 for structure learning. We show outputs of all
SLAs on datasets in Figure 2.6.

We update the scoring matrix P for this tier and compute weighted edge
confidence. We resolve contradictory edges between Tier 1 and Tier 2 by selecting
the highest weighted edge confidence of the two. We sum up the weighted edge
confidences and the resulting causal graph after Tier 2 is shown in Figure 2.5, (c).

Tier 3: Causal Knowledge from Literature In Tier 3, we go through
peer-reviewed literature for the problem domain. For this simulation, we assume
three causal information sets, L = {l1, l2, l3}, each of which is extracted from
individually published literature. The summary of causal relationships extracted
from the literature L is:

1. Literature 1 (l1): D → G, A → D
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2. Literature 2 (l2): F → G, E → G, D → G, C → F
3. Literature 3 (l3): B → E, C → F , D → E, D → G, E → G

Similar to the previous tiers, we update the scoring matrix P and compute
weighted edge confidence as well. We also resolve conflicting edges, (if any),
between new causal graph in Tier 3 and original causal graph after Tier 2,
depending on edge confidence. Finally, we sum up the weighted edge confidences
with previous tiers and the resulting causal graph after Tier 3 is shown in
Figure 2.5, (d). A summary of the edges with edge orientations and combined
weighted edge confidence is shown in the supplementary document, Table 3.

Edge Orientation In the last stage of edge orientation, we see whether any
cycles were created in the process. In case one is found, we follow edge orientation
process (as described in method section) and derive the updated SCM. We present
the eventual output in Figure 2.5, (e).

Here we present each individual structural causal models generated through
application of structure learning algorithms on the datasets. We have applied
SLA = {sla1 , sla2 } on dataset D = {d1 , d2 , d3 }.

Evaluation For evaluating our proposed method, we compare the output SCM of
the algorithm with the GTDAG. Specifically, we compare edges with directions from
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Figure 2.6: Structural Causal Models as outputs of Tier 2 in CKH

our proposed method with that of the GTDAG, and report the average accuracy,
along with precision, recall and F1 score. An edge-by-edge comparison of generated
output DAG with that of GTDAG is considered as a classification problem
[127, 111]. For the simulation, with a node number of q = 8, we check for

n
2



= 28

edges’ causal directions. On average, our proposed method achieved an average
accuracy of 89.29% (precision: 86.80%, recall: 89.29%, f1-score: 87.70%).

It is possible to incorporate incorrect causal knowledge due to biased
opinion, dataset, or publication. For this, we additionally perform sensitivity
analysis with perturbed edges within individual tiers. We randomly select three
edges and alter their directions. Specifically, we add the following information:

We run the simulation initially without any alteration, and then with
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id
A1
A2
A3

Change in simulation
Add false causal edge
Alter true causal edge
Remove true causal edge

Ground truth
C ...D
E→G
B→F

Altered information
C→D
E←G
B ...F

Table 2.2: Alteration in causal edges in the simulation

Agreement scores
Change in edge
Tier 1
No alteration
1.0
A1
1.0
Tier 1 A1+A2
1.0
A1+A2+A3
1.0
A1
1.0
Tier 2 A1+A2
1.0
A1+A2+A3
1.0
A1
1.0
Tier 3 A1+A2
1.0
A1+A2+A3
1.0

Tier 2
0.13
0.13
0.13
0.13
0.124
0.115
0.107
0.13
0.13
0.13

Tier 3
0.372
0.372
0.372
0.372
0.28
0.28
0.28
0.319
0.28
0.28

Metrics
Accuracy
0.8929
0.8571
0.8214
0.8214
0.8929
0.8929
0.8929
0.8929
0.8929
0.8929

Precision
0.8680
0.8438
0.8364
0.8364
0.8680
0.8680
0.8680
0.8680
0.8680
0.8680

Recall f1-score
0.8929
0.8770
0.8571
0.8427
0.8214
0.8244
0.8214
0.8244
0.8929
0.8770
0.8929
0.8770
0.8929
0.8770
0.8929
0.8770
0.8929
0.8770
0.8929
0.8770

Table 2.3: Iterations of simulations with false information injected in each tier

multiple perturbed edge directions. For each tier, we perturb one edge (A1), two
edges (A1+A2), and three edges (A1+A2+A3), and report the general accuracy,
precision, recall, and F1-score, along with the change in agreement scores in each
case. Table 2.3 shows the reported outcomes for each simulations.

In general, with gradual perturbation, performance metrics as well as
agreement scores decrease, however this decrease is not drastic, due to the weights
of tiers of CKH. For each tier, agreement scores decrease, however the decrease in
agreement score does not necessarily alter the outcome. In Tier 1, because of using
only one expert, performance metrics decrease more. In other tiers, since there are
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multiple knowledge source, wrong information from one source reduces the
agreement scores but does not change performance metrics much.
2.5

Discussion

Identifying causality is a critical part of many analyses, specifically in clinical
research where trust in models is low, and safety and efficacy of clinical decisions is
essential. In that context, SCM provides the theoretical foundation for identifying
causation from large datasets. However, the lack of methodologies to derive an SCM
for estimating causal effect is a fundamental research problem. We have proposed a
novel methodology to combine causal knowledge from various sources such as
experts’ opinion, data, and literature to derive domain-specific accurate SCMs. We
discuss the importance of causal information from sources other than just data, and
present the rationale behind using hierarchy of causal knowledge. As demonstrated
by our experiments, our proposed method (CKH) effectively identifies the most
compatible causal models, with higher accuracy and F1-score, from opinions of
experts working in the field, outputs of SLAs on existing data, and reported
information in peer-reviewed publications. Further discussion is addressed in the
appendix.

The CKH-driven algorithm relies on availability and abundance of causal
knowledge sources, making it unreliable when there is a lack of causal knowledge
from multiple tiers of sources (e.g., CKH-generated causal model from only data will
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have low confidence compared to that generated from all three sources). Similar to
other open research problems in causal inference, it cannot verify a ground-truth
SCM. An alternate to CKH is to not make strong inferences about causal directions
to build a DAG and rather derive a Markov equivalence class. Within individual
tiers under CKH for a specific problem domain, there is a challenge in finding and
selecting experts. Similar difficulty arises within Tier 3 (literature, CKL ), since
extraction of causal knowledge from literature is itself a research problem under
Natural Language Processing (NLP) [131, 62] and is currently being tackled by NLP
researchers.

Rationale with the Theory of SCM Finding the right and the
most-compatible causal model with the underlying data generating mechanism is
critical for estimating causal effects through rules of do-calculus. This is a
challenging research problem since data itself cannot differentiate between SCM
within a Markov equivalence class. It has been proven in a recent seminal work [13]
that additional complementary causal knowledge is needed along with data to
derive a SCM and the proposed methodology can be a strong tool to aid in that
process. Our proposed methodology uses a systematic approach to incrementally
derive the SCM with appropriated scoring for different levels of evidence and can
generate high accuracy even in the presence of contradictory causal connections.
The algorithm would be beneficial for applied causal inference researchers, specially
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in epidemiology, medicine and social sciences. Proposed CKH-driven algorithm
effectively estimates all necessary components of a computed SCM, U, V, F from all
tiers of causal knowledge and P (u) from Tier 2 (data) only. However, it also
produces weighted edge confidences CON F , which is a key contribution of this
algorithm. The edge confidence signifies the strength or confidence of information
we have on the specific edge, however it does not state anything about the strength
of causal relationships between variables or parameters of functions F .

Completeness of the Derived Causal Model The causal model estimated
through CKH algorithm is built through encoding of causal knowledge sources
iteratively and thus holds a summary of causal information from all possible and
relevant sources. The rationale for its completeness is that, hU, V, F, P (u)i, values of
four (4) components of the structural causal model derived with the proposed
CKH-driven algorithm, is curated from all the tiers of CKH (and thus contains all
necessary and relevant information needed to generate a complete outcome). This
collaborated information is also weighted appropriately based on the significance
and the impact of causal knowledge sources. Another key argument for
completeness of the derived causal model comes from the tier weights and their
usage. Till now, we have used an increasing weight for the three tiers
(WE < WD < WL ) for a well-researched problem domain, with sufficient experts,
data and publications available on the domain specific problem of interest. For an
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evolving problem domain (e.g., COVID-19 crisis), where we do not have an
abundance of well-established peer-reviewed literature, we can alter and adjust the
tier weights as fit for the problem at hand. For example, in estimating the effect of a
specific old drug in treatment of COVID-19 patients, we would have more weight on
Tier 2 (data, CKD ) compared to Tier 3 (literature, CKL ), simply because of lack of
strong evidence from literature and might use an alternative variation of tier weights
hierarchy (WE ≤ WD > WL ). For such reasons, we conjecture that CKH provides a
fundamental, necessary, and sufficient building mechanism for constructing
structural causal models for a problem domain, given causal knowledge from a
varying sources. A rigorous proof for the completeness is still under investigation.

Limitations of CKH and challenges of individual tiers The CKH-driven
algorithm relies on availability and abundance of causal knowledge sources, making
it unreliable when there is a lack of causal knowledge from multiple tiers of sources
(e.g., CKH-generated causal model from only data will have low confidence
compared to that generated from all three sources). Similar to other open research
problems in causal inference, it cannot verify a ground-truth SCM. An alternate to
CKH is to not make strong inference about causal directions to build a DAG and
rather derive a Markov equivalence class. Within individual tiers under CKH for a
specific problem domain, there is a challenge in finding and selecting experts.
Similar difficulty arises within Tier 3 (literature, CKL ), since extraction of causal
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knowledge from literature is itself a research problem under Natural Language
Processing (NLP) [131, 62] and is currently being tackled by NLP researchers.

Application in specific fields of Science Proposed CKH-driven causal model
generation has high impact for specific fields of science, and especially in health
science. Identifying the cause for an outcome and quantifying the causal effect is of
high importance in health science and epidemiology. An ongoing work is aiming to
derive a SCM for the treatment of delirium patients in the ICU [15] based on the
CKH. Other than that, CKH has implications in other branches of science, where
the notion of causality is critical, such as, sociology and finance.
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CHAPTER 3
A Causally Formulated Hazard Ratio Estimation through Backdoor
Adjustment on Structural Causal Model

3.1

Introduction

Experimental studies such as randomized controlled trials (RCT) are considered the
gold-standard in hypothesis testing. For safety and efficacy reasons and regulatory
purposes, most new drugs or treatments are studied through RCTs [38]. RCTs
provide the best mechanism to identify the causal effect of treatments or
interventions, by adjusting for observed and unobserved confounders under the
rubric of a potential outcome framework [29]. Despite clear advantages of RCTs in
drug-trials, in practice, they are expensive, time-consuming, and not feasible in
many cases due to ethical reasons. Other issues with RCTs include low recruitment
rate, loss to follow-up, insufficient sample size, and being prone to selection bias
[83, 31]. While RCTs remain the best way to establish causation, large amounts of
data captured with new technologies during routine healthcare (e.g., electronic
health records (EHR) or wearable devices), colloquially termed big health data, has
the potential to discover causal effects from observational studies to complement
RCTs. With proper methodological considerations, observational studies can
provide a way to emulate RCTs and go beyond statistical correlation [47, 49].

In the 1970s, the potential outcome framework was extended to observational
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studies to identify causal relationships from observational data through the Rubin
Causal Model (RCM) [105, 101, 54]. Recent advances in structural causal model
(SCM) provides the methodological framework under the potential outcome
framework for graphically formalizing the identification of causal effects from
observational and experimental data [89, 95]. SCMs can be used to emulate RCTs
from observational data in many cases if the graphical model is identifiable [14],
which signifies the capability of estimating the interventional distribution
(P (y|do(x))) from the available data with the assumptions incorporated in the
model.

Experimental studies (including RCTs) frequently explore and report
survival analysis measures. Survival analysis is the branch of statistics that analyzes
the expected duration of time-to-event with outcome statistics such as hazard ratio,
odds ratio, and risk ratio. Survival analysis has been well-studied under the
potential outcome framework with experimental studies and with RCM for
observational studies [20, 45]. Recent research has also studied survival analysis
with RCM for observational studies considering the data generating mechanism or
the study designs to estimate outcome statistics such as hazard ratio, odds ratio,
risk ratio, and risk difference [24, 51].

Commonly reported outcomes from survival analysis in experimental clinical
studies include the survival curve and hazard ratio (HR). The survival curve
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Figure 3.1: An example survival curve, collected from Girard et al. ([34])

graphically reports the hazard in a population and represents the fraction of the
population that survived in the treatment and the control group over time. HR
describes the comparative hazard between the treatment and the control group.
Hazard function, or simply hazard signifies the rate of events-of-interest (e.g., a
death) at time t, conditional on survival until time t and beyond [123]. For example,
we present a survival curve (Figure 3.1) as reported in [34], where probability of
overall survival of patients in drug groups (starting at 100%) is presented with time
passed, and the probability declines with time.

Even though HR is widely used in practice as a standard tool for
comparative evaluation of the outcome between treatment and control groups, it
depends on the length of the study and, by definition, has an inherent selection bias
(since only the survived population at time t are selected at time t + 1) [45]. In
addition, both the survival curve and HR do not consider the study design, that is
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RCT versus observational study, in their formalization. Consequently, it is difficult
to interpret the results of an intervention from only the reported hazard ratio [45]
and compare different studies with varying study designs and time lengths. The
researcher has to consider the design of the study, length of the study as well has
the hazard ratio to understand the effectiveness of the treatment. Structural causal
models (SCMs) provide a framework to explicitly define the design of the study, the
assumptions for the study, as well as the length of the study. However, to the best of
our knowledge, a framework to compute the hazard ratio with SCMs does not exist.

Previous approaches for adjusted survival curves under the rubric of RCM
used inverse probability weighting (IPW) to adjust for confounders in the estimand
[20]. However, this approach has a strong assumption, namely ignorability [106, 9].
The ignorability assumption states that there are no unobserved confounders in the
model, and the variables considered for IPW satisfy the backdoor criterion.
Although an approach with instrumental variable can be used when the treatment
assignment is non-ignorable [9], in practice, this is rather a strong assumption and a
variable can be a mediator, a collider, an M-bias, or a confounder [68]. In this
paper, we formulate the estimation of the hazard ratio from observational studies
under the rubric of SCMs that does not depend on the ignorability assumption. We
provide a principled approach to define observational studies using SCMs, redefine
with time-specific survival as outcomes (instead of survival time as the only

57
outcome), and therefore mathematically transform observational studies to the
corresponding experimental studies by adjusting for confounders with the backdoor
criterion and then, sample from the experimental studies to estimate hazard ratios.
We provide the mathematical formalization of the approach with a simple causal
graph and with detailed mathematical derivation, and validate the results with a
simulated data set and a benchmark data set on Ewing’s sarcoma.

3.1.1

Clinical Relevance

Most clinical research reports HR with survival analysis. However, the reported HR
and its process of calculation do not take into account the study design (e.g., RCT
vs. observational study) and corresponding assumptions (e.g., ignorability). This
makes it harder to compare the results of different studies with different study
designs, sample populations, study lengths and assumptions. Our proposed method
with SCMs estimates HR by explicitly describing the study designs and assumptions
for a better clinical understanding of the effect of the treatment of interest.

3.1.2

Technical Significance

We propose a novel approach to estimate the HR from observational studies with
SCM, taking the causal relationship between treatment and outcome into account.
In HR calculation for survival analysis of observational studies, our review of the
literature identifies a lack of causal interpretation. Our proposed approach first
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develops a time-invariant causal model and estimates the survival time after
adjusting for the confounders in the SCM using backdoor adjustment and
do-calculus. The development of an SCM enables us to identify the confounding
variables, unlike with the ignorability assumption where we adjust for every variable
available (except treatment and outcome), as well as properly adjust using the
minimal set, thus reducing computational requirements. The computed survival
times are considered “as-if” they were sampled from an RCT. The newly adjusted
survival times are capable of expressing the true causal effect of treatment on the
outcome through the survival curve and HR. We validate the proposed method in
both simulated experiments and with observational data.

3.1.3

Generalizable Insights

We propose a novel method of estimating the HR for observational studies under the
rubric of SCMs. The method can be used for any observational studies with survival
data, after defining the SCM. Our method of estimating the HR through SCMs
clearly defines the study-design and assumptions in the model. All the source code
for this study is shared with the research community through a GIT repository. A
Python-based library has been released that takes the data, the graph, and length
of the study as input and provides the adjusted survival curve with backdoor
adjustment and the hazard ratio as the output. Our approach is limited in the cases
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when i) the SCM is not defined and ii) the SCM is not identifiable through the
adjustment formula or backdoor adjustment (i.e., there is no backdoor set).
3.2

Related Work

Survival analysis [63] is a methodological approach for modeling and comparing the
time-to-event between two populations. The event is called a hazard, which can be
death, an adverse clinical event, or a mechanical failure for physical systems. It
compares the condition of survival in the treatment versus control group, and
reports outcomes with statistical measures such as the HR. Frequently reported
approaches in survival analysis include Kaplan Meier survival curve, Cox
proportional hazards model, life tables, and survival trees,. We review a
non-parametric approach of the Kaplan Meier survival curve and the
semi-parametric approach of the Cox proportional hazards model.

The Kaplan Meier survival curve [61] is a non-parametric statistic
representing the survival function and HR in the treatment and the control group.
It provides a visual comparison between survival functions in different treatment or
control groups; it does not differentiate between RCTs or observational studies.
Data from both of the approaches can be plotted as the Kaplan Meier curve. It is
up to the individual researcher to interpret and explain the Kaplan Meier curve
based on the study design. Cox PH model, on the other hand, is computationally
complex. However, it is a commonly used approach for survival analysis, and is
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widely used to compute the HR in epidemiological studies. The key aspect of it is
the underlying proportional hazards assumption [22], stating that the HRs of the
treatment and control group are proportional and is a function of the covariates. It
is a semi-parametric model since no assumption is made about the baseline hazard
function (i.e., hazard function with no covariates). In general, it is effective in
estimating both regression coefficients (βi ) and the HR [63]. Futher, it is unbiased
(when estimated considering all possible covariates).

We review existing approaches to compute the HR for observational and
experimental studies. Previous work on survival analysis for observational data with
RCM under potential outcome used IPW to adjust for confounders [20]. However,
RCM requires the ignorability assumption that all variables considered for
adjustment with IPW satisfy the backdoor criterion. In reality, a variable can also
be a mediator, and in those cases adjusting for the mediators will result in
inaccurate analysis. It has also been shown that the HR estimation approach has an
inherent selection bias [48, 45] as only the patients who survived at time t were
sampled at time t + 1 to be considered for the estimation. SCMs provide the
mathematical machinery to identify the backdoor variables given a causal graph.
We used the same Ewing’s sarcoma data set as studied in [20] with the same
assumptions (i.e., all the covariates satisfy the backdoor criterion) to arrive at the
same result as a validation strategy for our approach.
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For survival analysis, it was shown that in some cases the Kaplan Meier
curve may show no difference between the treatment and control groups when in
reality there is a statistically significant difference in the HR, if it is adjusted
properly [75]. The rationale behind this phenomenon is that a non-parametric
approach is used to plot the survival curve, whereas a semi-parametric method is
used to calculate the HR. The authors [75] presented an approach to construct a
plot of the survival curve consistent with the HR calculated. In this work, the
adjusted survival curve for a specific treatment group was estimated by calculating
a mixture of the estimated survival functions for separate strata, and weighted
based on the distribution of the covariate in the sample dataset. However, the
approach does not consider the design of the study in the survival analysis.

To extend the existing definition of the Cox PH Model, the Marginal
Structural Cox PH Model has been introduced and used to find the effect of
Zidovudine on the survival of HIV-positive men [52]. Statistical analysis in the
presence of time-dependent confounders is commonly done through a standard Cox
PH model. However, Robin [99] has previously shown that this approach cannot
adjust for all biases. Similar to previous work under the RCM, the authors used the
conditional ignorability assumption. This is a much stronger assumption compared
to using the SCM to identify confounding variables opening the backdoor. Several
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other researchers [109, 103] have used the IPW approach, although without using
SCMs.

The existing literature to compute the HR does not consider the study
design and might lead to misinterpretation if the data were not sampled correctly or
adjusted for the right confounding variables. While previous research alludes to this
problem, they do not provide the mathematical machinery for survival analysis.
Although the traditional Cox PH Model can minimize the effects of biases, it is not
the same as “adjustment” of confounding variables. The bias is reduced by fitting
the Cox PH regression model until convergence [22], it does not consider the study
design or the data generating mechanism. The model fitting approach does not
generate a causally meaningful interpretation despite reduction in biases. Our goal
is to formulate an approach that estimates the HR through a causal formulation
considering the data generating mechanism with SCM, that portrays the direct
causal effect of treatment on outcome, in terms of the HR metric. The assumption
of variables opening the backdoor path in the SCM as confounders and adjustment
on the dataset based on that enables a more causally interpretable estimation of the
HR.
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3.3

Background

3.3.1

Hazard Ratio

To define the HR, we use the hazard function [123] in the Cox proportional hazard
model:

p
X
βi Xi )
h(t, X) = h0 (t) exp(

(3.1)

i=1

Based on this, the Hazard Ratio (HR) is defined [63] as:

HR =

h(t, Xx=1 )
h(t, Xx=0 )

(3.2)

Here, h(t, X) represents the hazard function at time t and the vector with the
covariates of the model X. X can also be written as [w0 , w1 , ..., wm , z0 , z1 , ..., zn , x],
where x is the treatment, zi are the confounders, and wi are the other associated
covariates. Xx=1 represents the value of the covariate vector X with value of the
treatment set as 1 (x = 1), making Xx=1 = [w0 , w1 , ..., wm , z0 , z1 , ..., zn , 1]. β
represents the maximum likelihood estimates (MLE) for each covariate. In other
words, β is the corresponding coefficient for each covariate that fits the data into a
converging model for the Cox regression.

As expressed in Equation 3.1, the proportional hazard assumption defines
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the hazard function h(t, X) to be composed of the baseline hazard function h0 (t)
(i.e., hazard when all covariates are set to 0), multiplied with the exponential of the
sum of β multiplied by the corresponding covariate.

Since we have defined the HR and hazard function, we can simplify the
equation of the HR to:

HR =
=

h(t, Xx=1 )
h(t, Xx=0 )
h0 (t) exp(βx 1 + βz Z + ...)
h0 (t) exp(βx 0 + βz Z + ...)

(3.3)

= exp(βx )
In other words, the HR is equivalent to the exponential of the regression coefficient
β. However, computing β is non-trivial since, in practice, one does not know the
baseline hazard function (h0 (t)). We can only estimate the HR using the maximum
likelihood function, and iterating until the model converges to a pre-defined error
bound [63].

Although the HR is an important outcome, it has limitations in explaining
causal relationships. No causal mechanism is understood from the HR. This is
because the HR is calculated from the convergence of regression models and,
confounding and other such bias is handled by simply including the covariates to
the model. It is then up to the individual researcher to make sure that the right
data are used to measure the HR and interpret accordingly. For example, an HR
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calculated from an RCT provides the casually linked hazard for the intervention,
whereas the same HR calculated from an observational study simply provides a
correlated hazard. This existing approach simplifies the calculation and reduces the
burden on the researcher. However, we frequently find differences between the
survival curve and the HR. This difference, or bias, arises because of the inherent
definitions of the survival curve and Cox PH model.

3.3.2

Structural Causal Models

Structural causal models (SCMs), developed on the foundations of probabilistic
graphical models, draw inferences that explain the causal relationship between
variables. With an SCM, a causal model is defined first and is expressed with a
graphical representation. Definition 1 gives the formal description of an SCM:
[14, 89].

Definition 2 (Structural Causal Model) A structural causal model M is a
4-tuple hU, V, f, P (u)i where:

1. U is a set of background (exogenous) variables that are determined by factors
outside of the model,
2. V is a set {V1 , V2 , ..., Vn } of observable (endogenous) variables that are
determined by variables in the model (i.e., determined by variables in U ∪ V ),

66
3. F is a set of functions {f1 , f2 , ..., fn } such that each fi is a mapping from the
respective domains of Ui ∪ P Ai to Vi , where Ui ⊆ U and P Ai ⊆ V Vi and the
entire set F forms a mapping from U to V . In other words, each fi in
vi ← fi (pai , ui ), i = 1, ..., n, assigns a value to Vi that depends on the values of
the select set of variables (Ui ∪ P Ai ), and
4. P (u) is a probability distribution over the exogenous variables.

An SCM is often expressed by a causal graph G. Each node V in G
represents an observed or unobserved variable, and each directed edge E represents
the causal relationships between them. To find the causal effect of variable X on
variable Y , do-calculus is introduced [95]. Do-calculus is used to map the
observational reality to the corresponding experimental reality with the
identifiability equation by adjusting for different kinds of biases (e.g., confounding
bias), if it exists. The backdoor criterion provides a powerful tool to identify the
variables that need to be adjusted for this transformation (in other words, adjust for
confounding bias) and is defined in definitions 2 and 3.

Definition 3 (Backdoor Criterion) Given an ordered pair of variables (X, Y ) in
a directed acyclic graph G, a set of variables Z satisfies the backdoor criterion
relative to (X, Y ) if no node in Z is a descendant of X, and Z blocks every path
between X and Y that contains an arrow into X.

67
Definition 4 (Backdoor Adjustment) If a set of variables Z satisfies the
back-door criterion relative to (X, Y ), then the causal effect of X on Y is
identifiable and is given by the formula: P (y|do(x)) =

3.3.3

P

z

P (y|x, z)P (z)

Problem Definition

Our research problem is to develop a method to compute the HR for observational
studies by leveraging the SCM by explicitly declaring our assumptions and
adjusting for the right confounders. The goal is to acknowledge the defined roles of
variables in the SCM, and use a minimum set of confounders to adjust for backdoor,
thus building a computationally-efficient and more accurate model for objective
estimation and comparison. The algorithm will take three sets/inputs, (1)
observational dataset D consisting of treatment, outcome in survival-time and other
covariates, (2) SCM supporting the causal mechanism and dataset, G, and, (3)
length-of-trial T . At the completion of the algorithm, the output will be: (1)
adjusted survival curve S (non-parametric estimation), and (2) hazard ratio of
treatment, HR (semi-parametric estimation) (Figure 3.2). The assumption in our
approach is that the observational data are available, and the SCM is fully specified.
3.4

Methods

In this section, we formalize our approach to mathematically transform the
time-dependent observational data to the corresponding experimental data by
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Figure 3.2: Schematic overview of the proposed approach

leveraging the SCM. We then use the adjusted dataset for estimating HR using Cox
PH Model. Our proposed approach focuses on causal effect of treatment on outcome
to measure HR. We start with an observational study scenario and define all related
assumptions. The schematic diagram for the proposed approach is shown in
Figure 3.2, with observational data, corresponding causal diagram and the length of
study is provided as input. The approach first uses backdoor adjustment to create
sample data from experimental study, and then computes the hazard ratio from the
sampled experimental data.

3.4.1

Assumptions

We assume a simple observational study for a population, consisting of treatment
X, confounding variable Z, and outcome in survival time T . In this scenario,
treatment X is a dichotomous variable (X = 1 signifying treatment and X = 0
signifying control). Outcome T is the survival time from the beginning of the study
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Figure 3.3: Simple observational study (treatment X, outcome in survival-time T
and single confounder Z)

and is a continuous variable in time units. Although the confounding variables can
be a categorical or continuous variable, for simplicity, we assume the confounder Z
to be a dichotomous variable. This observational study can be expressed as an SCM
and with a graphical form G through causal directed acyclic graph (causal DAG) in
Figure 3.3, where treatment, confounder, and outcome is expressed by the nodes X,
Z and T respectively.

From the definition of the SCM, we can express the underlying functions
defining the causal relationships between variables by: Z ← fz (Uz ), X ← fx (Z, Ux ),
T ← ft (Z, X, Ut , h0 (t)). Here, U = {Ux , Ut , Uz } is the set of exogenous variables,
V = {Z, X, T } is the set of endogenous variables, f = {fz , fx , ft } is the set of
structural functions.

• fz (Uz ) shows that confounder Z is independent of any other endogenous
variables.
• fx (Z, Ux ) expresses the dependency of X on Z. Since Z is parameter for both

70
functions fx and fy , Z imposes a bias on the model
(P (X|Z = 0) 6= P (X|Z = 1)), and the function fx defines whether the bias is
strong or weak.
• ft (Z, X, Ut , h0 (t)) defines the effect of X and Z on the survival time T . This
function also depends on the baseline hazard function h0 (t, X) since this
defines the rate of decline in survival.

We also assume to know the sample size of population n and a maximum length of
survival time tmax .

3.4.2

Approach

Transformation of single study to multiple studies

Experimental studies commonly have different study time-lengths, e.g., different
number of days as the outcome endpoints (e.g., 30-day survival, 90-day survival,
etc.). This variable is a dichotomous variable and describes a patients’ status of
survival at the end of the study. While analyzing a study similar to these, we do not
take into account survival at each day, or survival after end-of-trial day, since we do
not have the opportunity to do so. In our problem definition, we only have the
survival time of individuals; however there is no defined end time for the trial. From
the individual survival time, We can easily get the i-th day survival of every
individual in the dataset, i being the number of days from the beginning of the

71
study. We use days as smallest unit of time, since we assume the dataset reports
survival in units of days. However, it could be any other units of times (e.g.
minutes, or weeks) depending on the problem domain and dataset.

Since our observational study has a maximum survival time of all individuals
tmax , we assume we calculate the variables Yi , signifying the i-th day survival, i
ranging from 0 to tmax . Conversion of continuous variable T describing survival time
into multiple variables Yi , each describing survival at the i-th day, essentially breaks
down the single observational study into tmax number of observational studies with
variables X, Z and Yi , each of which is now a dichotomous variable.
Through the transformation, from a single SCM G, we end up with n
different SCMs, each with the same treatment X and the confounder Z, but
different outcome (survival at i-th day). Note that, in our assumption, the causal
graph is time-invariant, i.e., the functional relationship between the variables does
not change over time. This conversion is represented by n different SCMs
(Transformed graphs A, Figure 3.4 (a)), where n ≥ tmax .
An important point to note here is that, the single confounder Z and
treatment X from the original observational study is not being transformed, only
the outcome is distributed into multiple variables. In other words, we assume a
point intervention and the confounding variables are invariant in time. And since we
are transforming from a single trial to multiple trials, the outcomes Yi s of these
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separate trials are not conditionally dependent on each other (e.g. a RCT with
30-day survival as outcome does not analyze about whether any patient died at 20th
day or 29th day.).

However, in extracting information from obs. data, there is dependency
between them. Specifically, Yi has causal effect on Yj (where j > i), since if Yi is 0
(e.g. patient died at i-th day), all Yj (where j > i) is 0 (e.g. patient remains dead for
all consecutive days). Also, Yi only has direct causal effect on Yi+1 , every other
corresponding effect is mediated through. If X has causal effect on Yi , it is mediated
through Yi−1 . For example, X ⊥
⊥ Y1 |Y0 , in absence of any backdoor variables.
Reasoning behind this assumption is that, without having any underlying effect of
treatment on outcome at i-th day, subject is suddenly prone to hazard on i + 1-th
day. For example, this is unlikely that, if a subject is advised a treatment (drug),
the subject has no hazardous effect until 10-th day and suddenly finds a hazardous
effect on 11-th day. It is possible that the subject does not show any symptom on
10-th day, or we cannot measure the internal hazardous effect of the drug on 10-th
day (due to lack of symptoms).

The relationship between Yi s is reflected through a single transformed SCM
(Transformed graph B, Figure 3.4 (b)), where n ≥ tmax . The similarities between
transformed graphs A and transformed graph B is that they both have same Z and
X, and the dissimilarities are:
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For outcome Y0

For outcome Y1

For outcome Yn

(a) Converted Causal DAGs with no dependency between Yi s

(b) Converted single Causal DAG with dependencies between Yi s
Figure 3.4: Converted Causal DAGs with survival time converted to binary outcome
of survival at different timepoints

1. Transformed graphs A portrays n different trials with different outcomes,
whereas transformed graph B is a single trial.
2. For transformed graphs A, Yi ⊥
⊥ Yj (where j 6= i), however for transformed
graph B, Yi 6⊥
⊥ Yj (where j 6= i).
3. Since two causal DAGs are different, transformed graphs A and transformed
graph B have two different equations for P (Yi |do(X)).

In summary, we transform the single observational study into multiple
different trials expressed through two different transformations (transformed graphs
A and transformed graph B, Figure 3.4), each with the same treatment X and
confounding Z, but with different survival time as the outcomes, as the death (or
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failure) increases over time. These outcomes are the status of survival (or death) at
i-th day, where i is 0 to n (n ≥ tmax ).

Generation of Survival Curve

Applying Backdoor adjustment formula in transformed graphs A, the causal effect
of X on Yi (for all n causal graphs) is:

P (Yi |do(X)) =

X

P (Yi |X, Z)P (Z)

Z

In transformed graph B, the causal effect of X on Yi is:

X

n
Y

Z,Yi−1 ,...Y1 ,Y0

k=0

P (Yi |do(X)) =

!
P (Yk |Yk−1 , ..., Y0 , X, Z)

· P (Z)

Since P (A|B, C)P (B|C) = P (A, B|C) (using rules of conditional probabilities), we
can reduce this equation to,

P (Yi |do(X)) =

X

P (Yi , Yi−1 , ..., Y0 |X, Z)P (Z)

Z,Yi−1 ,...Y1 ,Y0

Finally, for j <= i, P (Yj = 1|Yi = 1) = 1 (e.g. if a person is alive at 30th day, he
has been alive for the last 29 days as well),
P (Yi = 1, Yi−1 = 1) = P (Yi−1 = 1|Yi = 1)P (Yi = 1) = P (Yi = 1), which reduces our
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equation down to the same as that of transformed graphs A:

P (Yi = 1|do(X)) =

X

P (Yi = 1|X, Z)P (Z)

Z

This signifies whether we use transformed graphs A or transformed graph B,
we end up with same adjustment formula.

For each of the newly transformed causal DAGs, we can now adjust for the
confounder using the backdoor adjustment formula. We calculate adjusted
probabilities Padj and thus adjusted counts Cadj for each of the n causal graphs.
Using the values of Padj , we generate survival curve with Kaplan Meier fitter.

Calculation of Hazard Ratio

Since we calculated Cadj for each of n causal graphs, we know number of adjusted
individuals alive at each unit (day) of time. This helps us build back the adjusted
survival time Tadj for individuals, as it was in the original dataset. The newly
calculated survival time Tadj is adjusted for the confounding bias, as if they were
sampled from an RCT. We measure the HR using Cox PH model with the adjusted
survival time Tadj as outcome.
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Algorithm

Algorithm 1 generates adjusted Kaplan Meier curve as well as the HR from Cox PH
model on the adjusted dataset. The input for the algorithm is the dataset,
specifically, confounder Z, treatment X, survival time T , and event status S. In the
algorithm, variables in uppercase letters signify vectors, and variables in lowercase
signify single variables. Internal procedures convert single to multiple trials
(Algorithm 2) are shown separately.
Algorithm 3 Causally Formulated Hazard Ratio Estimation
1:
2:
3:
4:
5:
6:
7:
8:
9:
10:
11:
12:

procedure CFHRE(Z, X, T, S)
global n ← length(T )
global tmax ← max(T )
Yi ← convert single to multiple trials(T, S)
while i ← 0 to tmax do
P
adj pi ← Z P (Yi = 1 | X, Z)P (Z)
adj ci ← adj pi ∗ count(X)
survival curve ← plot(time, cumulative(adj pi ))
adj X, adj T ← convert multiple to single trial(adj ci )
model ← cox ph model(adj X, adj T )
HRdrug ← exp(model.βdrug )
return survival curve, HRdrug

Algorithm 4 Conversion of single trial to multiple trials
procedure convert single to multiple trials(T, S)
2:
while i ← 0 to tmax do
3:
while j ← 0 to n do
4:
Yi [j] ← ((T [j] <= i) & (S[j] = 1)) ? 0 : 1

1:

5:

return Yi
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3.5

Experiments and Applications

We evaluated the proposed approach for computing HR and visualizing survival
curves with an experimental and observational dataset: (1) a synthetic dataset
derived from a linear acyclic model with Gaussian noise; (2) a real-world dataset on
disease-free survival in patients with Ewing’s Sarcoma [75]. The rationale to
consider these two datasets are: (1) both of the underlying causal model has a
backdoor path through confounders, and, (2) both these datasets have treatment
and control group that satisfy the proportionality hazarads assumption.

3.5.1

Experimental Data

We simulate an observational study with n = 200 patients. A subgroup of the
patients received a treatment (X = 1), and the remaining patients did not (X = 0).
We generate data on survival time T (in days) defined as the outcome. The
treatment assignment is confounded by sex (e.g. Z = 1 for female, Z = 0 for
others). The scenario has a causal model as depicted in Figure 3.3.

For the simulation, we generated outcome variable survival-time through
defining a baseline hazard function. We defined survival time to be exponentially
varying with time, in the form of: T ← a.exp((b + cZ + dX + eZX) ∗ i) + E, with Z
being confounder, X being treatment, E being the noise/error and i being the index
of patient. The other parameters were set to
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a = 5, b = 0.025, c = 0.005, d = −0.015, e = 0.075, E = U (−0.5, 0.5), they were
selected such that the HR remains close to 1, however injection of bias through Z
portrays different outcome in survival curve.

We simulate the study with a strong biased effect from confounder Z. We
define the strength of bias by an imbalance of conditional probabilities in each
stratum of Z through the function fx (Z, Ux ). For the defined strong bias case,
P (X = 1|Z = 0) = 0.75 and P (X = 1|Z = 1) = 0.25. It translates to, if Z = 0
stands for females in this trial, 75% received the drug, whereas, in Z = 1 or others,
only 25% received the drug. In a randomized controlled trial, under a
no-confounding-bias scenario, we should have
P (X = 1|Z = 0) = P (X = 1|Z = 1) = 0.5.

After we generate the experimental data, we applied Algorithm 1. We
compared the existing approach of survival curve and survival curve from the
adjusted dataset side-by-side in Figure 3.5. Figure on left shows significant
difference in survival curve between treatment and control group. The treatment
population (X = 1) seems to be more prone to hazard compared to the control
population (X = 0). Figure on right shows adjusted survival curve to be
overlapping, signifying no significant difference in hazard rate in both the treatment
and the control population.
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Figure 3.5: Unadjusted survival curve for simulated data (left) and, survival curve
generated after applying proposed approach (right)

Hazard Ratio
(95% Confidence Interval)

Existing model
Proposed model
Observational data
Observational data
excluding confounding variable including confounding variable Transformed and adjusted data
(biased estimate)
(traditional approach)
1.66
0.80
1.00
(1.25-2.20)
(0.57-1.12)
(0.76-1.33)

Table 3.1: Hazard Ratio for simulated dataset, calculated using existing model and
our proposed approach

Table 3.1 presents the HR found in the fitted Cox PH model in three
different processes:

1. using only the treatment and outcome from the original dataset,
2. using data of all covariates (treatment, outcome and confounder) from the
original dataset, and
3. using only the treatment and outcome from the adjusted dataset following our
proposed approach.

First column reports a biased estimate of HR, by using only treatment and
outcome (excluding confounder) in Cox PH model. The second column reports a
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standard estimate of HR, by including all known variables (including confounder).
The third column reports HR calculated in our proposed approach, using only
treatment and outcome (excluding confounder). The first approach represents
scenarios where: 1) we ignore confounding, assuming it does not impact the
treatment, or, 2) we do not possess data on the confounding variable (unmeasured
confounding). This approach, however, results in an incorrect approximation of the
HR. The second approach represents the existing approach to calculate HR. The
third one shows our approach, and it eliminates the need for using confounding in
model fitting since we are already adjusting for that.

Here, in Figure 3.5, the difference in unadjusted survival curve is similar to
fitting Cox PH model with only X and T , leaving out Z, as found following the first
approach generating HR=1.66. On the other hand, the overlapping adjusted
survival curve is validated by calculated HR, following both the existing approach
with the Cox PH model (HR=0.8) and our algorithm (HR=1.0).

3.5.2

Ewing’s Sarcoma Data

We also applied the proposed method to a real-world dataset of patients with
Ewing’s Sarcoma [75]. The dataset was selected based on its survival data and
known causal DAG consisting of confounders. The dataset consists of a total of 76
Ewing’s sarcoma patients with disease-free survival days as the outcome. 47 of the
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Figure 3.6: Unadjusted survival curve for Ewing dataset (left) and, survival curve
generated after applying proposed approach (right)

patients received a novel treatment (S4), and 29 received (one of) three (S1—S3)
standard treatments.

The level of Serum lactic acid dehydrogenase (LDH) acted as the confounder,
since high LDH levels indicated a lesser likelihood of treatment assignment along
with an impact on survival time. In our analysis, we marked patients receiving S4
as the treatment group (X = 1) and patients receiving S1-S3 as the control group
(X = 0). We applied our algorithm on this data set and the survival curve with the
existing approach. Results of our algorithm is shown in Figure 3.6. Figure on left
presents treatment group (X = 1) to be less hazardous than control group (X = 0).
Figure on right is the adjusted survival curve with mostly overlapping survival
curves of two groups, although treatment group (X = 1) seems slightly more prone
to hazards. The adjusted survival curve shows similar results, as demonstrated in
Makuch et al. [75]. We also present the calculated HR following the three processes
described in the earlier subsection. In Table 3.2, the HR calculated by our approach

82

Hazard Ratio
(95% Confidence Interval)

Existing model
Proposed model
Observational data
Observational data
excluding confounding variable including confounding variable Transformed and adjusted data
(biased estimate)
(traditional approach)
0.53
1.12
1.04
(0.30-0.96)
(0.59-2.11)
(0.57-1.87)

Table 3.2: Hazard Ratio for Ewing dataset, calculated using existing model and our
proposed approach

(HR=1.04) differs from the HR calculated in the traditional way (HR=1.12),
presenting the drug to be a little less hazardous. However, the 95% confidence
interval for both of these coincide, signifying that the true value lies within this
range. The first column reports a biased estimate of the HR based on only the
treatment and outcome (excluding confounder) in Cox PH model. The second
column reports a standard estimate of the HR that includes all known variables
(including the confounder(s)). The third column reports the HR calculated in our
proposed approach, using only the treatment and outcome (excluding the
confounder). The reason for getting an accurate estimate of the HR even when
excluding the confounder is because we adjusted the dataset beforehand using a
minimum set of confounders from the SCM, thus focusing on the true causal effect
of treatment on outcome.
3.6

Discussion and Conclusion

We propose a novel method to estimate the HR using the Cox PH Model through
the transformation of observational data to corresponding experimental data
leveraging an underlying SCM. The transformed data are mathematically
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Figure 3.7: Two example graphs where the backdoor adjustment will produce different
results compared to an approach based on the ignorability assumption

guaranteed to be adjusted for the confounding bias with the assumption that the
SCM represents the data generating mechanism. Previous approaches under RCM
that estimate the survival curve use the ignorability assumption, and will not work
when the variables selected do not satisfy the backdoor criterion. Ignorability
assumption states that, distribution of the potential outcomes (Y (0), Y (1)) is
independent of the treatment variable by randomly assigning treatment:
{Y (0), Y (1)} ⊥
⊥ X. An extension of the idea, conditional ignorability states,
distribution of the potential outcomes (Y (0), Y (1)) is independent of the treatment
variable (X), conditional on the covariates (Z): {Y (0), Y (1)} ⊥
⊥ X|Z. Using
conditional ignorability for adjustment on covariates allowed researchers to draw
inferences from observational studies as well; however, adjusting all covariates
irrespective of their causal relationship with treatment and outcome can contribute
more bias to the model and incorrect estimation of causal effects.

We present two scenarios as example in Figure 3.7 (in the left hand side, X
is the treatment, Y is the mediator, and M is a mediator. For the second graph, Z
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acts as a confounder as well. The left hand side is the example of a mediator and
the right hand side graph is known as the front-door setting.). In the first scenario
(Figure 3.7, left), we show an SCM with treatment X and outcome Y with a third
covariate M . Here M acts as a mediator in between X and Y , thus the backdoor
adjustment gives a null set, meaning no adjustment is needed. The do-calculus
formula would be: P (Y |do(X)) = P (Y |X). Adjusting on M based on conditional
ignorability will produce an incorrect estimation of causal effect. In the second
scenario (Figure 3.7, right), we discuss a setting called front-door adjustment where
we identify the variables to be adjusted with two applications of backdoor
adjustment [89]. In an SCM with a mediator (shown in Figure 3.7 (right)), the
covariate M does not satisfy the backdoor criterion and acts as a mediator between
treatment X and outcome T . Thus, adjusting with M irrespective of its role as
mediator will produce a biased estimate of the HR. The accurate backdoor
adjustment formula (with M as mediator) is
P (Y |do(X)) =

P

M

P (M |X)

P

X

P (Y |X, M )P (X). However, adjustment by

assuming M (and Z) as confounder gives an incorrect adjustment formula:
P (Y |do(X)) =

P

M,Z

P (Y |M, X, Z)P (Z)P (M ). Our approach (with backdoor

criterion) can correctly identify the variables to be adjusted for estimating HR using
SCM and do-calculus.

Both the survival curve and the HR help to build a strong interpretation of
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the survival analysis of an experiment. The HR is most frequently reported as it
summarizes the overall effect of treatment. However, survival curve encodes
information on changes in survival over time [45], which, in certain cases gives us
better insight. Our proposed method is capable of generating both the survival
curve and the HR, along with proper backdoor adjustment based on the underlying
SCM. The HR calculated from the adjusted dataset requires only the treatment and
outcome variables, and thus relies on direct causal relationships of treatment and
outcome. For this purpose, we assume knowledge of the true causal model, an
absence of unmeasured confounders, functional relationship in the SCM being
time-invariant, and, proportionality of the HR in the outcome. In reality, defining
the causal graph with SCM, that is, causal structure learning, requires a principled
approach. The development of statistical and computational algorithms for causal
structure learning is an active research area [44, 104], and, is not well-established in
the current literature. We are currently working on a methodological framework to
develop the causal graph with structure learning algorithm and domain expertise.
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CHAPTER 4
Pragmatic Clinical Trials in the Rubric of Structural Causal Models

4.1

Introduction

Experimental studies with varying designs and research goals, such as Randomized
controlled trials (RCT), Pragmatic clinical trials (PCT), are frequently conducted in
many branches of science to derive the causal effect of interventions. Conversely,
observational studies (OBS) capture the outcome of an incident without any
alteration of the independent variable. Due to differences in the experiment settings
(e.g., goal, population group, treatment protocol), the causal findings of the
experiments are harder to compare, and the transfer of knowledge from one study
population to another is not very trivial. Thus, there is a need for generalizability
or structural methodology to draw unbiased causal inferences from experiments
(RCT+PCT+OBS), leveraging their unique design attributes.

In recent times, through the advancement of machine learning and artificial
intelligence, finding newer ways of causal explorations from datasets available, i.e.,
data-driven causal inference, is of high interest. Structural Theory of Causation
(SCM), proposed by Judea Pearl [95] and extended by many other researchers [14],
holds the potential to define scientific studies for causal inference, express them
through graphical causal models and transfer knowledge in between them.

SCMs allow researchers to represent scientific studies systematically. SCM
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representation of an experimental study helps portray underlying causal
mechanisms, express causal effects of interventions and answer hypothetical
questions. However, core differences of PCT from RCT and OBS [32], in terms of
(a) population, (b) setting, (c) comparison arm (treatment), and (d) outcome,
makes it challenging for objective evaluation of interventions and their effect. This
paper illustrates a causal representation of PCT and relevant mathematical
formulations to aid causal effect estimations and objective evaluations in a target
population and interpret existing analysis techniques through a causal lens.

Contrary to RCT and OBS frequently being formulated through SCM [95],
representation of PCT with SCM is still an ongoing research problem [50].
Additionally, novel ways of utilizing priors (background knowledge) to build a
comprehensive causal model from data is also under exploration [86]. In summary, a
standardized way to represent PCT through SCM is not yet fully grounded on the
theories of recent advances in causal inference.
4.2

Background

This section describes the relevant background concepts, such as various
scientific studies, including pragmatic clinical trials and their unique attributes. We
then discuss the structural theory of causal within causal inference and structural
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causal models for various scientific studies. Finally, we present our problem
formulation, followed by related works.

4.2.1

Experimental Studies

In broader terms, based on design factors, scientific studies follow two routines:
experimental studies and observational studies. Experimental studies are at the core
of most scientific investigations. In experimental studies, experimenters introduce a
dependent variable (e.g., treatment or procedure) and consecutively observe an
outcome [19]. Most commonly, the underlying research question is uncovering the
effect of an outcome compared to an intervention or factor.

The design of experimental studies is a well-explored research area [28, 27].
The most popular and effective experimental study, especially to find causal
relations, is the randomized controlled trial (RCT) [39]. In RCTs, researchers
explore the effects of treatment on outcome in a narrower population (with clear
and strict inclusion-exclusion criteria) with randomization (to control for both
known and unknown confounding) [32]. RCTs are harder to implement and cost
more; however, they unquestionably justify the causal effect of treatment by
comparing treatment arms.

Since experimental studies require significant resources (in time and
expenses) and are sometimes unethical or infeasible for a certain population,
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researchers occasionally conduct studies through exploring existing real-world data
(e.g., EHR dataset) collected without any intervention. These studies are called
observational studies (OBS) (or, natural experiments) [100]. RCT and OBS are
inherently different from each other, the two prime differences being (a) presence of
intervention, (b) de-confounding through randomization. In general, RCTs are
considered as a higher level of evidence compared to OBS [21].

One other type of experimental study is pragmatic clinical trials (PCT). By
nature, PCTs are more fluid and have characteristics floating between an RCT and
an OBS.

4.2.2

Pragmatic Clinical Trials

Definition

Pragmatic clinical trials (PCT) are a variety of experimental studies that aim to
explore correlations between treatment and outcome in a real-world health system,
contrary to focusing on causal explorations [81]. Uncovering causal effects through
experimental studies requires extreme deconfounding and strict inclusion-exclusion
criteria, sometimes making the study result irrelevant to real-world practice. The
goal is to define clinical decision-making rather than regulatory approval. Two
significant challenges of PCT are: (1) missing data and (2) non-adherence to
protocol.
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Features

Due to its pragmatic nature, features of PCT have drawn much discussion from the
scientific community. [32] defines PCT as a variation of RCT, with four critical
pragmatic design elements: (a) real-world population (recruitment extended to fit
all potentially eligible individuals receiving care in participating setting), (b)
real-world setting (commonly takes place in a flexible setting closer to patients’
usual clinical care, avoiding the need for specially trained research staff for data
collection), (c) appropriate comparison arm (sometimes combining multiple drugs or
multiple doses of the same drug), and (d) relevant outcome (goal is to understand
the real-world implications of the intervention). [74, 98] have laid out nine features
of PCT, depicted as a wheel in Figure 4.1 (lower score signifies explanatory and
higher axis signifies pragmatism in nature).

Analysis Methods

Since the treatment population group varies based on adherence and
loss-to-follow-up in PCTs, various analysis protocol is followed in the data
investigation of PCTs. The three most common analysis protocols for PCT are (1)
Intention-to-treat (ITT), (2) As-treated (AT), and (3) Per-protocol (PP).

In Intention-to-treat (ITT) analysis, all randomized patients are included,
regardless of whether they adhered to the treatment prescribed or subsequent
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Figure 4.1: Visualization of PRECIS (PRagmatic Explanatory Continuum Indicator
Summary)

withdrawal [40, 79]. It essentially ignores anything after randomization (e.g.,
withdrawal, protocol non-compliance), and in general, avoids overoptimistic
estimates of the intervention efficacy. For this reason, ITT is the most recommended
method in PCTs [40, 17].

In As-treated (AT) analysis, patients are incorporated based on the
treatment they received, irrespective of their randomization status [117]. Likewise,
in per-protocol (PP) analysis, only those patients are included who genuinely
adhered to the study prescribed, i.e., for whom the treatment prescribed and
treatment received are same [112]. PP analysis represents a ‘best-case’ scenario in
trial results since it represents patients who completed the treatment initially
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allocated and thus ignores protocol deviation or non-adherence. Both AT and PP
analyses give a biased estimate of intervention efficacy; however, they are essential
for the report since they reflect the impact of non-compliance and non-adherence.

4.2.3

Structural Causal Models

The structural theory of causation was proposed and established on the foundations
of probabilistic graphical models by Judea Pearl [95] and many other researchers
[14, 119]. Under this theory, structural causal models (SCM) are a structured
definition of a causal model, often portrayed through graphs. We present the formal
description of an SCM [89] in Definition 5:

Definition 5 (Structural Causal Model) A structural causal model M is a
4-tuple
hU, V, f, P (u)i where:

1. U is a set of background (exogenous) variables that are determined by factors
outside of the model,
2. V is a set {V1 , V2 , ..., Vn } of observable (endogenous) variables that are
determined by variables in the model (i.e., determined by variables in U ∪ V ),
3. F is a set of functions {f1 , f2 , ..., fn } such that each fi is a mapping from the
respective domains of Ui ∪ P Ai to Vi , where Ui ⊆ U and P Ai ⊆ V Vi and the
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entire set F forms a mapping from U to V . In other words, each fi in
vi ← fi (pai , ui ), i = 1, ..., n, assigns a value to Vi that depends on the values of
the select set of variables (Ui ∪ P Ai ), and
4. P (u) is a probability distribution over the exogenous variables.

Causal directed acyclic graphs (DAG) are commonly portrayed to express an
SCM. In a causal DAG G, node V represents an observed or unobserved variable,
and directed edge E represents the causal relationships between two nodes. With
the purpose of investigating the causal effect of one variable on another, do-calculus
was developed [95]. Do-calculus is a multi-functional tool (mathematical
formulation) to map the observational truth to the corresponding experimental
reality by adjusting for different kinds of biases, such as confounding (if it exists).

4.2.4

SCM for Scientific Studies

SCM and causal DAG have been frequently used in the literature to represent
various scientific studies [125]. Figure 4.2 shows two graphical structures of SCM,
one for observational study (left) and the other for randomized controlled trial
(right). Both of them have treatment X, outcome Y , and confounder Z; the only
distinction being a lack of arrow (causal connection) from Z to X, thus representing
the randomization done prior to the study. Representation through SCM helps
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Figure 4.2: SCM representation of scientific studies

provide a structural definition to distinct trials and allows application of do-calculus
for causal effect estimation and counterfactual evaluation.

4.2.5

Problem Definition

Since the strength of SCM in representing different studies and exploring the
underlying causal mechanisms is well-established in the literature, researchers are
looking for ways to represent PCT using the rubric of SCM. For this work, we focus
on the two following research questions:

1. how can we represent PCT through SCM?
2. how can we represent the analysis techniques commonly deployed in PCT
using SCM and do-calculus?

4.2.6

Related Works

For causal exploration on PCT, different general guidelines have been proposed in
the literature; however, a unified approach is severely lacking. [50] discussed issues
involving pragmatic trials in general, along with a general causal graphical structure
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and adherence as a node in the graph. Without using any underlying causal
structure, [81] have presented an elaborated guideline for a causal understanding of
diverse, unique features of PCT qualitatively and figuratively to estimate the ITT
and PP effects (of both point and sustained intervention). Later, in continuation to
the previous two works, [80] discussed a wide variety of graphical representations of
PCTs, but without employing any do-calculus for ITT or PP effect estimations.
Although all the works used causal graphical structures for representing PCTs, they
did not decide on a single definition or discuss its use with do-calculus for ITT, AT,
or PP analysis.
4.3

Structural Causal Model for Pragmatic Clinical Trials

In this section, we introduce the notion of structural causal models (SCM)
for pragmatic clinical trials (PCT). We iterate through the unique features of PCT,
such as eligibility criteria, non-adherence, and loss-to-follow-up, and examine their
potential interpretations in structural causal models. Following that, using the
notations proposed, we discuss the frequently used analysis methods for PCT, such
as intention-to-treat, as-treated, and per-protocol analysis. For simplicity, we
assume a point intervention with no time-varying components (both in treatments
or outcomes).
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Figure 4.3: Graphical representation of the proposed structural causal model for
pragmatic clinical trials

4.3.1

Defining PCT for SCM

To express a PCT through SCM, we start with defining the PCT. We assume, we
are working with a P CT with population group Π, where the query of interest is
finding the effect of a treatment protocol X (not the same as ‘causal’ effect of
treatment X, explained in section 4.3.1) on outcome Y . Different arms of treatment
protocol X might have overlapping components, such as the same drug (or software
feature) with a different dosage (or color palette). We propose that the target P CT
for the population Π can be expressed through a structural causal model
M =< U, V, F, Pu >, with a graphical representation through graph G, with two
versions of treatment X and X 0 .

Equivalent RCT

For reference and comparison, if the query of interest for the researchers were, in
fact, finding the ‘causal’ effect of treatment X on outcome Y , the standard
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Figure 4.4: Graphical representation of the structural causal model of a RCTP CT ,
(left) with population Πs & treatment X (= X 0 ), and (right) with population Πs as
a selection bias through node S on population Z

procedure would be to conduct a randomized controlled trial (RCT) on a stricter
population group Πs . In that case, the causal graph for the RCT would be similar
to Figure 4.4 (left), where treatment would be X(= X 0 ). The reasoning behind
having different population groups for PCT (Π) and RCT (Πs ) comes from their
definitions; Πs would be a narrower focused group of Π with minimal possible
confounding to outcomes. We will refer to this equivalent RCT as RCTP CT .

4.3.2

Features of PCT

Treatment, Outcome and Covariates

A general graphical representation G of the proposed SCM M for PCT is presented
in Figure 4.3. Here, the independent variable, or treatment, is represented by X
(and X 0 , explained in next subsection), and Y represents the dependent variable or
outcome. Covariates Z and Z 0 represents all other relevant variables; however, Z do

98
not have any causal effect in adherence to the trial (i.e., X 0 ), whereas Z 0 are the
covariates that affect adherence (e.g., affects treatment received X 0 ).

Since X is provided through randomization, there is no causal relationship
(→) between Z or Z 0 and X. However, as Z 0 are indicators of adherence, there is a
causal relationship between Z 0 and X 0 .

Non-adherence

Since non-adherence to treatment is a core component in P CT , they are depicted
through two separate nodes X and X 0 in the proposed causal graph. X represents
the treatment prescribed (through randomization), and the treatment received (or
followed by trial participants) is represented by X 0 . X 0 is different from X due to
non-adherence; however, it is still influenced by X. The relationship between X and
X 0 has previously been expressed [80] through adherence to the trial, as a
percentage of adherence to the treatment prescribed.

Eligibility criteria

Compared to RCTs, PCTs are more liberal in including patients from varying
demographics. As previously discussed in section 4.2, eligibility criteria are the key
reason behind this population demographic difference between a PCT and a similar
RCT, and thus, between Π and Πs . This difference can also be viewed as a selection
[12] through node S, where S = 1 defines being eligible for the RCT, equivalent to
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the target PCT. However, selection through node S in a study does not always
trigger selection bias to that study.

Loss-to-follow-up

In most PCTs, population lost-to-follow-up is a concern for the scientists [32]. Since
trial participants tend to show lesser adherence to the protocol, some generally do
not follow through with the treatment prescribed or disconnect with the research
team and end up being the population lost-to-follow-up. During data analysis, this
population data lost-to-follow-up are generally censored [50]. The conditioning of
censored data can also be viewed as survivorship bias [18], through a node C. For
C = 1, we select a population group who completed the trial and were not
lost-to-follow-up, thus looking at a population who ’survived’ the study.

4.3.3

Outcome Analysis for PCT

Query of Interest

By definition, the query of interest in a PCT is finding the ‘effectiveness’ of a
treatment protocol, not the ‘efficacy’ of specific treatment [97]. Based on that, [80]
have described the vital causal interests in a P CT : intention-to-treat effect, the
per-protocol effect of continuous adherence to treatment versus placebo, and in
general, the effect of good adherence to trial protocol versus poor adherence in the
placebo arm.
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Intention-to-treat Analysis

In the intention-to-treat analysis, we explore the effects on outcomes based on
randomized or prescribed treatment. Since all the participants (in some cases,
excluding loss-to-follow-up) are included in this analysis, we express the concern by:

P (Y |X)

(4.1)

As-treated Analysis

For as-treated analysis, by definition, we look for participants who indeed took the
treatment rather than prescribed, so the “true” treatment intervention would be X 0 ,
not X. For that, we express the concern by:

P (Y |X 0 )

(4.2)

Per-protocol Analysis

Finally, we include the population who followed through treatment prescribed for
per-protocol analysis. We exclude the population who have taken a different
treatment than what was prescribed; that is, for whom X and X 0 did not match.
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With this, we express the concern by:

P (Y |X = a, X 0 = a)

(4.3)

Additional Study Metrics

Pragmatic clinical trials additionally report other relevant study metrics, such as
Odds Ratio (OR), Risk Ratio (RR), and Hazard Ratio (HR) [23]. These metrics are
used to detect the association of treatment with the outcome and provide additional
insight into treatment effects. We present equations to calculate their values based
on conditional probability below. In Equation 4.6, h(t, Xx=a ) represents hazard
function with time t and the vector with the covariates of the model X with the
value a (X = [z, x], where x is the treatment and z are the confounders).

P (Y =0|X=1)
P (Y =1|X=1)
P (Y =0|X=0)
P (Y =1|X=0)

(4.4)

P (Y =0|X=1)
P (Y =0|X=1)+P (Y =1|X=1)
P (Y =0|X=0)
P (Y =0|X=0))+P (Y =1|X=0)

(4.5)

h(t, Xx=1 )
h(t, Xx=0 )

(4.6)

OR =

RR =

HR =
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Figure 4.5: Hypothetical PCT in patients with cardiovascular disease. Intervention,
A = medical management + surgery, vs. control, B = medical management only.
Collected from McCoy et al. [76]

Given a known structural causal model, interpreting their causal equivalent
is established in the literature: causal odds ratio & causal risk ratio [88] and
causally formulated hazard ratio [3].
4.4

Example of PCT with SCM

In this section, we apply definitions and assumptions from section 4.3 to represent a
hypothetical PCT through SCM, and leverage Equation 4.1, Equation 4.2,
Equation 4.3, Equation 4.4, Equation 4.5, and Equation 4.6 on the dataset to find
relevant treatment effects and outcome metrics.

For this purpose, we leverage a hypothetical pragmatic clinical trial,
discussed in [76] and presented in Figure 4.5. In this PCT, an investigator
conducted a study to evaluate whether the addition of surgery to a conventional
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medical therapy would benefit the patients (e.g., effective in controlling death in
patients with cardiovascular disease). A total of two hundred (200) patients were
enrolled, and half of them were allocated the new treatment protocol. The
intervention treatment group received a combination of medical management and
surgery, whereas the control group received only medical management.

Assumption of Ground Truth With the usage of this dataset, we are also
assuming the ‘ground truth’ that the surgical intervention does not affect outcomes.
Researchers are searching for this ‘ground truth’; one of the ways to do that is to
conduct this hypothetical PCT.

Study Timeline Overview As shown in Figure 4.5, after randomization, both
arms of intervention contained a total of 100 patients. The medical management
continues from randomization, and there is a timeline gap or waiting period of six
(6) weeks from randomization to surgery. In treatment group A, 15 patients died
before the six-week waiting period, and an additional 15 died between six weeks and
12 months. Similarly, 15 patients died before six weeks in treatment group B, and
another 15 died between six weeks and 12 months.
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Figure 4.6: Graphical overview of SCM representation of the example PCT

4.4.1

SCM for PCT

Using definitions from section 4.3, we represent the PCT through a SCM, as
represented graphically in Figure 4.6. X is the treatment prescribed after
randomization, where the population was divided equally between two treatment
protocols. X 0 is the treatment received, different from X due to patients (count of
15) not going through surgery within six weeks. Y is the outcome, death in a year
for this trial. Although our graph shows Z and Z 0 , we do not have any data on
record on these two for this specific PCT.

4.4.2

Outcome Analysis

We reorganize the trial dataset to count patient outcomes for each value of X, X 0 ,
and Y .

Application of equations from section 4.3 are presented in Table 4.2. The
calculated results match with the results reported in [76] and show that the
equations discussed hold their originality, with the addition of SCM for a better
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X
Treatment
Treatment
Treatment
Treatment
Treatment
Treatment
Treatment
Treatment

X0
Treatment
Treatment
Treatment
Treatment
Treatment
Treatment
Treatment
Treatment

A
A
A
A
B
B
B
B

A
A
B
B
A
A
B
B

Y
No death
Death
No death
Death
No death
Death
No death
Death

Count
70
15
0
15
0
0
70
30

Table 4.1: Population distribution for different values of treatment prescribed X,
treatment received X 0 and outcome Y

ITT
RR

=

P (Y =0|X=1)
P (Y =0|X=0)

=

15+15
70+15+0+15
0+30
0+0+70+30

= 0.3
0.3
= 1.00
OR

AT

P (Y =0|X=1)
P (Y =0|X=1)+P (Y =1|X=1)
P (Y =0|X=0)
P (Y =0|X=0)+P (Y =1|X=0)

P (Y =0|X=1)
P (Y =1|X=1)
P (Y =0|X=0)
P (Y =1|X=0)
0.3
1−0.3
0.3
1−0.3

P (Y =0|X 0 =1)
P (Y =0|X 0 =1)+P (Y =1|X 0 =1)
P (Y =0|X 0 =0)
P (Y =0|X 0 =0)+P (Y =1|X 0 =0)
P (Y =0|X 0 =1)

=
=

P (Y =0|X 0 =0)
15+0
70+15+0+0
15+30
0+15+70+30

= 0.18
0.39
= 0.46
P (Y =0|X 0 =1)
P (Y =1|X 0 =1)
P (Y =0|X 0 =0)
P (Y =1|X 0 =0)
0.18
1−0.18
0.39
1−0.39

PP
P (Y =0|X=1,X 0 =1)
P (Y =0|X=1,X 0 =1)+P (Y =1|X=1,X 0 =1)
P (Y =0|X=0,X 0 =0)
P (Y =0|X=0,X 0 =0)+P (Y =1|X=0,X 0 =0)
P (Y =0|X=1,X 0 =1)

=
=

P (Y =0|X=0,X 0 =0)
15
70+15
30
70+30

= 0.18
0.3
= 0.60
P (Y =0|X=1,X 0 =1)
P (Y =1|X=1,X 0 =1)
P (Y =0|X=0,X 0 =0)
P (Y =1|X=0,X 0 =0)
0.18
1−0.18
0.3
1−0.3

=

=

=

= 1.00

= 0.34

= 0.51

Table 4.2: Outcome metrics for the PCT

understanding of the trial. Similar results can also be estimated through the
equations provided from datasets used in other similar studies for PCT [79, 59].
4.5

Discussion and Conclusion

In this work, we have discussed the notion of leveraging structural causal models
within causal inference to represent pragmatic clinical trials. Our proposition, along
with relevant data analysis on the simulated PCT dataset, shows a prospective path
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of exploring PCTs for treatment effect estimations, counterfactual analyses, and
transportability methods explorations.

Strengths The essential contribution of this proposition is the notion of
leveraging SCM for expressing PCTs. SCM and relevant causal inference
methodologies have already been highly beneficial in estimating causal effects for
different experimental and observational studies [124]. PCTs are highly meaningful
for decision-makers as they are easier to conduct and convey treatment efficacy in a
standard-setting. Since PCTs are more fluid in their nature than other experimental
studies, the need to draw causal estimations from PCT is also higher than others.
The uniqueness of this proposition is defined by the usage of X and X 0 representing
treatments as two causally connected yet different variables.

Causal Equivalent of Guidelines for PCT The four key design elements of
PCT, by definition [32], are real-world population, real-world setting, appropriate
comparison arm, and relevant outcome. Excluding only real-world settings, the
SCM definition for PCT can utilize all the other elements. The concept also reflects
and pairs perfectly with the guidelines provided by [81].

Causal Interpretation of Analysis Equations Given an OBS with X as
treatment, Y as an outcome, and Z as confounders, we easily find the conditional
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probability of outcome Y given X [P (Y |X)]. To find the equivalent causal effect, we
either conduct a similar RCT with treatment randomized (aka de-confounded) and
look at P (Y |X) or simulate the RCT from the OBS using do-calculus
(P (Y |do(X))). Resembling to that conversion of P (Y |X) to P (Y |do(X)), we
explore causal effects from the equations Equation 4.1, Equation 4.2, and
Equation 4.3 by applying do-calculus on these. It results in:

P (Y |do(X)) = P (Y |X)

P (Y |do(X 0 )) =

X

(4.7)

P (Y |X 0 , Z 0 )P (Z 0 )

(4.8)

P (Y |X = a, X 0 = a, Z 0 )P (Z 0 )

(4.9)

Z0

P (Y |do(X = a), do(X 0 = a)) =

X
Z0

Equation 4.7, Equation 4.8, and Equation 4.9 provides two interesting
insights to the notion proposed.

(1) Since X is randomized, Equation 4.8 is equal to its equivalent conditional
probability equation. This estimation is the most standard (unbiased) estimation in
providing treatment effect, which also aligns with [79]. Nevertheless, it still cannot
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minimize bias introduced by loss to follow-up, as X 0 is not considered in this
equation. Equation 4.8 does not use X but uses X 0 , and is deconfounded by using
Z 0 . The effect estimation is helpful, but the causal estimation requires a knowledge
of measured confounders Z 0 , which is hard to find in the real world. This equation is
also valuable since it shows the effect of non-adherence on the trial participants
(through X 0 ). Equation 4.9 uses both X and X 0 in estimating the effect, by which it
captures the essence of the population who strictly adhered to the protocol.
(2) Although X and X 0 represent treatment in different population
percentages, they still fundamentally represent the same treatment for the study.
While conducting a real-life PCT, with patients lost to follow-up, the ITT analysis
results do not match with AT analysis results. Under normal conditions, P (Y |X)
and P (Y |X 0 ) would never be equal. However, with do-calculus, it is expected that
P (Y |do(X)) and P (Y |do(X 0 )) would be the same since they both indicate the
causal effect of treatment on outcome. It raises the idea that, if we can identify a
true set of confounders Z 0 (that affects adherence), we can estimate the true causal
effect of treatment on outcome from a PCT, and in those cases, Equation 4.7,
Equation 4.8, and Equation 4.9 will all produce the same effect estimate.

Limitations The prime challenge is defining the relevant causal structure for the
SCMs representing the PCT. RCTs (and Obs) are frequently expressed through
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SCMs; however, that does not happen with PCT due to their pragmatic nature by
definition. Researchers continuously explore ways to build causal structure through
data and priors (background knowledge, peer-reviewed literature). Another critical
challenge in this research is to find an appropriate set of confounders Z 0 .
Confounding variables, in most cases, are not observed, measured, or even found.
Finally, in PCTs, the treatment prescribed generally differs from the treatment
received. Thus, adherence to the trial is vital, and causal effect estimation becomes
complex when the information is unavailable or hard to determine.

Future Works Our future work will include instrumental variable analysis [12],
by using treatment X in Figure 4.4 as an instrumental variable for the proposed
causal graph. We will additionally explore time-series intervention with the
definition proposed, in place of point intervention, by altering the SCM and related
transportability equations.
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CHAPTER 5
Causal Discovery on the Effect of Antipsychotic Drugs on Delirium
Patients in the ICU using Large EHR Dataset

5.1

Background and Problem Statement

With a focus on the theoretical development of causal inference methodologies in
the previous three chapters, this chapter aims to discuss a practical, real-world
application of the causal inference framework to untangle unknown healthcare
information. For this purpose, we look into Delirium patients in the ICU.

Delirium (or acute brain failure) [35] is a disorder or disruption of
consciousness, presenting with a reduced capacity to focus, sustain, or shift
concentration. Delirium occurs in about 80% cases in the Intensive Care Unit (ICU)
and is associated with a more extended hospital stay, increased mortality for each
additional day with Delirium in the ICU [96] and other clinical complications such
as self-extubation and removal of catheters. Two of the significant issues in
diagnosing and treating delirium patients are:

• Currently, no biomarker exists to diagnose Delirium; rather, Delirium is
diagnosed with subjective assessment tools such as the confusion assessment
method (CAM) [57, 130]. This diagnosis requires the presence of a physician
active in the medical center and makes the diagnosis and detection of Delirium
patients in the real-world challenging.
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• Delirium is commonly treated with antipsychotic drugs (APD) [35] such as
Haloperidol, Ziprasidone, Olanzapine, etc. However, multiple randomized
controlled trials (RCTs) have shown either conflicting or inconclusive results
about the efficacy of APD in the treatment of delirium [82, 42]. This has
created a controversy over the efficacy or safety of APD in treating Delirium.

RCTs have been considered the gold standard since the 1960s [38]. The goal
was to identify the causation of diseases and understand the causal effect of drugs
by the regulatory bodies such as the FDA and clinical communities. The key ideas
behind RCT are:

• By random assignment of treatment or interventions, the confounding bias,
i.e., the bias due to the assignment of treatment or presence of other variables,
can be removed from the estimand, including the unobserved confounders.
• By comparing similar population groups of treatment and control arm, an
estimation can be made about treatment efficacy in the target population
group.

However, RCTs have their own set of challenges as well. RCTs have become
increasingly time-consuming, costly, and are often infeasible for safety and efficacy
reasons [31]. Thus there is a need to find alternatives to RCTs, possibly to detect
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Figure 5.1: RCT for Antipsychotics-based treatment for Delirium
causal effects from other sources of information and aid in removing controversies of
treatments in the field.

Recent advances in technology and the adoption of computerized systems in
routine healthcare have enabled the collection and curation of large volumes of data
during routine healthcare, albeit with confounding biases. At the same time, recent
advances in the theory of causal model, more specifically structure causal models
(SCM), provides the framework for adjusting for these confounding biases in many
cases. This removal of biases can be done (sometimes even if the confounders are
unobserved) from observational data using adjustment formulas such as
backdoor/front door criterion [14, 95, 120]. However, this approach requires
developing a graphical representation of the problem domain with meticulous
scrutiny of the variables’ relationship, structure learning algorithms, clinical
experience, and existing literature.
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With the availability (collection, storage, maintenance) of large-scale data in
different branches of science (healthcare, finance, sociology) and technology
(connected health, smart home), opportunities exist to extract necessary
information from it. Big data has aided in the revolution of neural networks,
advanced reinforcement learning, and improved statistical machine learning
methodologies. Most research advancements integrating big data revolve around
curve fitting and correlation. However, without causal relationships, scientists lack
the power of intervention or to even explore hypothetical scenarios (counterfactuals).

Big data is responsible for many breakthroughs and advancements in
healthcare, contributing to improved treatment policy solutions and collaborated
information from multiple sources. Although most breakthroughs are based on
predictive models, causal relationships are more crucial for healthcare. This has led
to countless experimental trials (randomized controlled trials, case-control studies)
on finding the efficacy or impact of an intervention on target outcomes. Causal
inference leverages big data and contributes to finding causal information,
sometimes even without experiments. One of the strengths of causal inference
methodologies is to draw conclusions on causal effects from observational data.
Causal inference and its potential with big data are not limited to healthcare only;
it has shown great potential in other fields (finance, sociology, law) as well
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[53, 85, 113]. Artificial intelligence is iteratively improved with research work and is
getting better at decision making and predictive modeling.

Since RCTs cost a lot in terms of money and time, emulation of RCTs from
the observational dataset can help reduce them. It also would aid in using datasets
from all over the world to find causation in other diseases and health complexities.
While RCTs are the gold standard for identifying causal effects of interventions, it is
time-consuming and costly. On the other hand, the data collected during routine
care, such as electronic health records (EHR), might also be valuable to generate
insight, identify the disease pathway and estimate the effect of interventions using
recent advances in methods for causal inference.

We aim to study the efficacy of APD in the treatment of Delirium using
retrospective cohort analysis. We plan to use the Causal inference framework to
look for the underlying causal structure model, leveraging the availability of large
observational data on ICU patients. It will help us to untangle the causal
relationship between variables and look into the counterfactual world (what-if). To
explore safety outcomes associated with APD, our research work targets to develop
a causal model for Delirium in the ICU using large observational data sets. We aim
to utilize the MIMIC III database, an extensive electronic health records (EHR)
dataset with 53,423 distinct hospital admissions [4]. Our null hypothesis is: that
there is no significant difference in outcomes for delirium patients under different
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Figure 5.2: Target observational study from large EHR data

drug-group in the ICU. If successful, our research work should help clear the
common controversy over prescribing APDs as well as shed light on the underlying
causal mechanism triggering Delirium in ICU patients. In other words, we propose
the following specific aims.

1. Create and curate three cohorts for patients with Delirium in the ICU from
MIMIC EHR data.
2. Develop structural causal models (SCM) with the domain expertise to
integrate clinical knowledge and probabilistic information from the data to
estimate the causal effect of interventions.
3. Validate the models with statistical methods and independent data sets.

Epidemiologists have continuously involved causal inference tools, such as
causal structure learning algorithms, in identifying underlying causal structures.
The process is impactful since it generates a causal model based on the information
available (data, literature, expertise), leading to a better understanding of the
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disease ecosystem; and estimates causal effects based on that. This creates a
potential to explore Delirium-treatment-related controversies through observational
datasets. Different studies have taken different paths; few studies [128, 2] have used
specific SLA algorithms to detect a causal DAG applicable for a targeted research
question, whereas others [110, 10] have assumed the causal structure from literature,
and validated them using datasets available. We plan to create a similar
computational pipeline for Delirium patients in the ICU inspired by these.
5.2

Method

To create a data cohort on Delirium patients in the ICU, along with relevant
covariates, we seek help from MIMIC-III [58], a publicly available large electronic
healthcare dataset. MIMIC-III is curated for twelve (12) years (2001-2012) and
holds information on around 53k distinct hospital admissions with around 40k
distinct patient histories. The database is well-maintained, de-identified, and open
for researchers (with necessary and relevant access protocol) to explore and
investigate.

The general process starts with appropriate data mining and data
preparation process. We plan to extract information regarding Delirium patients
(based on relevant ICD-9 code) and related covariates (decided upon exploring
literature). We then move forward with the data analysis protocol, which consists of
three (3) types of analysis:
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• Exploratory analysis: to explore data distribution and dataset properties
• Machine learning-driven analysis: to infer primary point of interest (i.e.,
primary outcome) based on all available covariates, as a standard approach to
prediction
• Causal analysis:

– Causal structure generation: to regenerate underlying causal model
through various structure learning algorithms
– Causal effect estimation: to evaluate the ‘true’ causal effect of treatment
on our defined points of interests

5.3

Results

This section describes our data curation protocol in detail, along with data
exploration and analysis. We present our general findings based on those steps
taken.

5.3.1

Covariate Selection

We start the process by defining the research questions (Is Haloperidol better at
treating Delirium patients in the ICU, compared to no antipsychotics or other
antipsychotics, such as Ziprasidone, Olanzapine, etc.?). We formulate this question
based on controversies present in existing literature (described in the background
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sex
age
race
sofa
apsiii
surgery
sepsis
dementia
alzheimers
anxiety
met. acidosis
airway obs.
liver disease
heart disease
mechvent.
time to mechvent.
drug group
drug categories count
death in hospital death timeline
length of stay

icd9 codes
pneumonia
depression
copd
mechvent. count
drug timelength
time in mechvent.

Table 5.1: Features in MIMIC-Delirium

section). Our null hypothesis is that there is no significant difference in target
outcomes for Delirium patients under different antipsychotics treatment groups in
the ICU. We define the treatment as the antipsychotics prescribed after being
diagnosed with Delirium in the ICU, with three different arms (Haloperidol, no
antipsychotics, and other antipsychotics). Our primary outcomes are (1) patient
death in hospital and (2) patient death timeline (death in 30 days / 90 days / a year
/ survived more than a year). Our secondary outcomes are (1) length of stay in the
ICU and (2) time put in mechanical ventilation. A total of fifty (50) relevant
covariates are explored and marked, which are closely correlated with our points of
interests (primary and secondary outcomes) for Delirium patients in the ICU.
However, due to the lack of availability of all covariates in the observational dataset,
we opt for the most significant twenty-eight (28) covariates, as listed in Table 5.1.
Here, the drug group (Haloperidol, no drug, other drugs) is the treatment provided.
Primary outcomes are death in hospital & death timeline, and secondary outcomes
are the length of stay & time in mechvent.
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These all together defined a target trial that we plan to emulate. The target
trial is inspired by existing RCTs done on delirium patients to find the effects of
antipsychotics and is designed to minimize the effect of confounding variables and
(selection) bias. Based on these, we start our data curation process from the
MIMIC-III dataset.

5.3.2

Data Curation Process

To determine eligible Delirium patients, we look into patients with ICD-9 code 293.0
(Delirium due to conditions classified elsewhere) [55]. We extract relevant
information about the patients from admissions, icu stays, and diagnoses icd table
to form the base dataset. We then infuse it with information from cptevents,
d icd diagnoses and prescriptions tables, and other views presented in the public
repository of the database (sofa, apsiii, ventdurations) [78]. We merge all
information together to create our target dataset of 1398 patients. We name this
curated dataset as MIMIC-Delirium for future references.

5.3.3

Data Overview & Exploratory Insights

After our data curation to create MIMIC-Delirium dataset, we successfully extract
1671 ICU stays with 1445 hospital admission counts on 1398 unique patients and
their relevant 28 covariate information. In terms of treatment provided in the ICU,
we found 681 (40.75%) were given Haloperidol, 528 (31.60%) were given other
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Figure 5.3: Data mining protocol (simplified)

Figure 5.4: Data distribution on age in years (left) and length-of-stay in days (right)

antipsychotics and 462 (27.65%) were given no antipsychotics. In terms of outcome,
311 (18.61%) had death in 30 days, 108 (6.46%) had death in 90 days, 175
(10.47%) had death in a year, and 253 (15.14%) survived at least a year
(information on 821 (49.13%) were unknown). Among the common associated
diseases in the ICU, 375 (22.44%) had Sepsis, 484 (28.96%) had Pneumonia, 1035
(61.94%) had (a variation of) heart diseases, and 97 (5.80%) had (a variation of)
liver diseases. Figure 5.4 shows the general data distribution on age in years skewed
to right since Delirium is frequent in elderly population and length-of-stay in days
(skewed to left since higher number of ICU stay is severe and rare).
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Additionally, we had findings such as mean length-of-stay and max
length-of-stay is higher for patients in the Haloperidol drug group, most patients,
who were given multiple APD, were given Haloperidol, The Haloperidol group has a
higher death rate in a year than the other two groups, etc.

For the statistical analyses, we conducted a one-way between-subjects
ANOVA to compare the effect of the drug group on length of stay in Haloperidol, no
drug, and other drugs group. With p < 0.05, we found a significant effect of the
drug group on the length-of-stay. Post hoc comparisons by the Tukey HSD test
indicate that the mean score for the Haloperidol group (mean: 7.47, deviation: 8.55)
was significantly higher compared to no drug group (mean: 4.12, deviation: 5.66)
and other drugs group (mean: 5.44, deviation: 6.14).

5.3.4

Predictive Analysis on MIMIC-Delirium dataset

Before our deep dive into causal exploration, we briefly explored the
MIMIC-Delirium dataset for predictive analysis. We employed standard supervised
classification algorithms on the complete dataset, with all 24 covariates (discarding
the output features) as features and death in hospital as the label. We deployed
10-fold cross-validation with Logistic Regression, Support Vector Machine, and
XGBoost algorithm. Mean accuracy with Logistic Regression is 89.71%, mean
accuracy with SVM is 89.11%, and test-mlogloss-mean for XGBoost (with 50 rounds
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Figure 5.5: Correlation heatmap of MIMIC-Delirium

of boosts) is 0.2724. For XGBoost, we also find that length-of-stay and age have the
highest impact in predicting outcome death in this case, which is self-explanatory.
Figure 5.5 shows the general correlation between features as a heatmap.

5.3.5

Causal Analysis on MIMIC-Delirium dataset

Our causal analysis is built upon two steps: (1) causal structure generation and (2)
causal effect estimation (based on causal structure generated).

Causal Structure Generation

To generate the most feasible underlying causal structure from the MIMIC-Delirium
dataset, we rely on causal structure learning algorithms (SLA), with assumptions of
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causal sufficiency and faithfulness. Specifically, we apply eight (8) causal structure
learning algorithms: (1) PC, (2) FCI, (3) GES, (4) GIES, (5) GDS, (6) LINGAM,
(7) MMHC, and (8) MMTABU, with help from existing R libraries: (1) pcalg
[60, 43] and (2) pchc [126]. With the application of these SLAs, we have eight (8)
individual causal graphs. However, we apply majority voting to each edge to merge
all this information together. This merging defines an edge as being present in the
final graph if it is present in more than 50% cases (more than four graphs).
Although this is a straightforward and naive solution to merge multiple causal
graphs, we employ this ensembling method since no standard has been established
in the literature yet. Figure 5.6 shows the final merged causal graph generated.

Causal Effect Estimation

With the causal structure generated, we now focus on causal effect estimation. For
this purpose, we employ the pipeline proposed by Microsoft Do-Why library [114]:

• Modeling
• Identification
• Estimation
• Refutation

With modeling completed as part of the causal structure generation step, we
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Figure 5.6: Combined Causal Graph for Delirium in the ICU (blue: treatment, red:
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now focus on causal effect identification and estimation. Based on the causal
structure generated, we identify the conditional probability equation for the four
target outcomes. Specifically, we express the do-calculus operations [13] in order to
‘virtually’ manipulate the outcomes. The do-calculus equations are presented below:
• P (death in hosp|do(drug group)) =

P

• P (death timeline|do(drug group)) =

age

P

P (death in hosp|drug group, age)P (age)

age

P (death timeline|drug group, age)P (age)

• P (los days|do(drug group)) =
P

heart disease,mechvent

P (los days|drug group, heart disease, mechvent)P (heart disease, mechvent)

• P (time in mechvent|do(drug group)) =
P

age,mechvent

P (death in hosp|drug group, age, mechvent)P (age, mechvent)

We now find the causal effect estimates based on these causal expressions
identified. In Table 5.2, we present the causal effect estimations, as Average
Treatment Effects (ATE), for treatment, aka, drug group on the four target
outcomes. As shown in the table, the causal effect of treatment on death in
Delirium and death timeline is very close. However, any drug, Haloperidol (1.8372)
and other drugs (1.6102), does much better in reducing hospital length of stay
compared to the no drug patient group (-0.0533). In addition to that, any drug
performs better (8.1912) in reducing time in mechanical ventilation compared to no
drug (4.4827), and Haloperidol does better (12.3007) than any other drugs (8.1912).

We now move to the final stage of causal effect estimation, which is the
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Hal. vs. No Drug
Other Drug vs. No Drug
Hal. vs. Other Drug

Causal effect of drug group on:
death in death
length of stay time in
hospital timeline in days
mech. vent.
0.0310
-0.1291
1.8372
12.3007
0.0216
0.0373
1.6102
8.1912
0.0113
-0.1386
-0.0533
4.4827

Table 5.2: Outcomes estimation in Average Treatment Effects (ATE)

refutation of the estimated effect. We do so in four different steps: by adding a
random common cause to the causal model, adding an unobserved common cause to
the causal model, using a Placebo treatment, and using a subset of data. The
expectation for these four is that:

• Adding a random common cause: should not change the estimated
outcome from before since this should be adjusted by use of do-calculus
expressions
• Adding an unobserved common cause: should change the estimated
outcome from before since the unobserved confounder induces non-removable
biases in the system
• Using a placebo treatment: should be close to zero since placebo
treatment should not have any impact on the outcome
• Using a subset of data: should not change the estimated outcome from
before since underlying data distribution did not change
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Application of these four steps results in the following values, which also
align with our expectations for a stable causal model and estimated effect:

• Estimated effect: 0.0309
• Add a random common cause: 0.0310
• Add an Unobserved Common Cause: 0.0262
• Use a Placebo Treatment: 0.0003
• Use a subset of data: 0.0319

5.4

Discussion

We have explored a potential observational study on Delirium patients in the ICU
in this study. Our curated dataset is analyzed through two lenses: regular
observational analysis and ‘simulated’ randomized controlled trial through the
structural theory of causation. We have multiple novel contributions to this research
work:

• Our observational study creates a prospective data cohort (MIMIC-Delirium)
for Delirium patients
• Data properties for MIMIC-Delirium provides insight into the general patient
demography in the ICU
• Machine learning-driven analysis on MIMIC-Delirium presents usage of
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prediction-based computational modeling and these algorithm’s general
strengths
• Causal analysis on MIMIC-Delirium found:

– No significant impact (X) of Antipsychotics choice in one of the primary
outcomes, death in hospital
– No significant impact (X) of Antipsychotics choice in length of stay in the
ICU; however, usage of any drug shows better outcome (X) compared to
that with no drugs
– Haloperidol performs better (X) in affecting time in mechanical
ventilation, compared to the similar impact of usage of other drugs or no
drugs,

Our study relies on a few underlying assumptions. We assume that the
Delirium patients in the ICU represent general Delirium demography since it occurs
more frequently ( 80% cases in ICU) in the ICU compared to other traditional
medical settings. Additionally, in generating the causal structure, we did not
incorporate any background knowledge from peer-reviewed literature because of the
existing controversies over the usage and benefits of Antipsychotics on the Delirium
population (discussed in the background section). One of the critical limitations of
our study is the lack of involvement of experienced physicians actively working in
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the ICU. Their involvement can aid in disputing general confusion in different parts
of the study; however, bias from their understanding needs to be handled by
involving multiple physicians. This limitation can be mitigated in future work.

In summary, our proposed analysis and pipeline create pathways for similar
studies, especially in the healthcare research domain. The abundance of curated
large electronic healthcare data presents a potential to find unexplored insights in a
specific population group. Causal inference, especially the structural theory of
causation, holds the potential to handle such research questions, look for causal
insights, and report them appropriately.
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CHAPTER 6
Conclusion and Future Work

6.1

Broader Impact and Summary Contribution of this dissertation

Search for causality is one of the core research questions in the healthcare research
domain. Causal Inference is a great tool, built upon statistics and curated heavily
for data science. Although many researchers are poking at exploring controversial
research questions through Causal Inference, this dissertation primarily focused on
the unexplored paradigms connected with various kinds of studies (RCT, Obs.,
PCT) conducted in the healthcare research domain. Our motivation was to improve
the current shortcomings of healthcare research through the eyes of an
ever-expanding data science arena.

The dissertation proposes novel methodologies on various critical points of
Causal Inference methodologies directed at aiding Healthcare research. We have
summarized the contributions in the following segments.

Our first study (CKH for SCM) proposes a novel methodology to compare
and combine causal knowledge from multi-dimensional sources, such as experts’
opinions, data, and literature, to derive domain-specific accurate SCMs. The
methodology is incredibly beneficial for applied causal inference researchers,
especially in the scientific fields of epidemiology, medicine, and social sciences, where
insight into causal mechanisms is highly sought after. Additionally, our proposed
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methodology allows adjustments of tier weights as fitted to work with shifting and
evolving problem domains, such as the COVID-19 crisis. The process relies on the
availability and abundance of causal knowledge sources, which faces challenges of
curating experts in the field or extracting causal knowledge from literature (NLP).

Our second study (Causally Formulated HR) uses do-calculus to estimate
causally formulated Hazard Ratio on survival dataset. Our proposed approach alters
the original SCM into multiple SCMs with different endpoints. Doing so enables us
to calculate conditional probabilities and thus backdoor adjustment on SCM. Our
approach does not alter the original definition of HR; however, it formulates HR
through alteration of SCM, which in effect uses only the causal effect of treatment
on outcome. The notion is highly impactful since, through the transformation of
SCM and backdoor adjustment, we get rid of biases from confounders and look at
the causal survival effect of treatment on the outcome through hazard ratio.

Our third study (PCT through SCM) contributes to the ideation and use of
structural causal models (SCM) for pragmatic clinical trials (PCT), commonly
conducted in healthcare research. Our goal behind this representation of PCT
through SCM is that, we expect PCT to be holding hidden causal information. Our
idea shows the interaction and comparison between treatment provided and
treatment received (which differs from treatment provided due to low adherence to
PCT) through do-calculus equations. Our study has addressed vital design elements
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of PCT: real-world population, real-world setting, appropriate comparison arm, and
relevant outcome. The ideation of PCT through SCM would enable healthcare
researchers to analyze more varieties of PCTs and other relevant trials. However,
the prime challenge still remains in finding a suitable causal structure.

Our fourth and final study (MIMIC-Delirium) presents an application of
Causal Inference methodologies in a specially curated dataset from a large EHR
dataset. Our observational study has created a prospective data cohort for Delirium
patients in the ICU. Analyzed data properties for MIMIC-Delirium have provided
insight into the general patient demography. Our machine learning-driven analysis
on MIMIC-Delirium has presented the strengths of prediction algorithms. Our
causal analysis of MIMIC-Delirium has found:

• No significant impact of Antipsychotics choice in death in hospital,
• No significant impact of Antipsychotics choice in length of stay; however, any
drug does better than no drugs, and,
• Haloperidol performs much better than other Antipsychotics or no drugs in
affecting time in mechanical ventilation.

6.2

Future Work

The dissertation project has multiple directions it can be extended to. The causal
knowledge hierarchy for causal structure estimation is a theoretical proposition; it
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has the potential to be applied in specific problem domains. Although our research
focus specializes in the healthcare domain, it can be significantly appropriate in
other branches of science also, such as sociology, finance, agriculture, etc. On top of
that, each tier of CKH has its category of knowledge sources. This categorization
creates the potential to further extend within the tiers and investigate accordingly.

Our estimation of hazard ratio through the adjustment to the structural
causal model is a pioneer in bridging traditional statistical methodologies with the
newer concept of the structural causal model. This work can be extended to
exploring time-varying interventions for various studies. Calculation of causally
formulated hazard ratios for specific applications, such as the real-world trial of the
effect of Antipsychotics in the Delirium patient group or the effect of COVID-19
vaccines in target population groups, is also a possible applied outcome of this work.

In expressing pragmatic clinical trials through structural causal models,
further research can be extended by exploring instrumental variable analysis by
using treatment X as an instrumental variable. It can also be expanded to analyze
time-series interventions with the definition proposed in place of point interventions.

Finally, in our applied work on Delirium patients in the ICU and the efficacy
of Antipsychotics on them, this dissertation can be expanded in multidimensions.
Our proposed framework can be used to analyze other relevant procedures, such as
survival analysis or Cox regression analysis. In terms of Delirium, additional
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correlated variables can be extracted to ensure a better fitted causal model and
better prediction efficiency. A collaboration with ICU physicians can be done to
generate an external validation dataset or create new trials. Regarding similar
healthcare problem domains, the proposed framework can be recreated for other
controversial research questions, such as the causal model for sepsis.
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